Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9496328,initial half-life,"Using the immunoassay, after i.v. administration initial half-life was 1 hour and terminal half-life was 10 hours (half-life was prolonged after extravascular administration, suggesting rate-limiting absorption).",Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496328/),h,1,1555,DB00644,Gonadorelin
,9496328,terminal half-life,"Using the immunoassay, after i.v. administration initial half-life was 1 hour and terminal half-life was 10 hours (half-life was prolonged after extravascular administration, suggesting rate-limiting absorption).",Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496328/),h,10,1556,DB00644,Gonadorelin
,9496328,Total serum clearance,"Total serum clearance was 2.6 L/h, and steady, state volume of distribution was 14 L.",Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496328/),[l] / [h],2.6,1557,DB00644,Gonadorelin
,9496328,"steady, state volume of distribution","Total serum clearance was 2.6 L/h, and steady, state volume of distribution was 14 L.",Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496328/),l,14,1558,DB00644,Gonadorelin
,9496328,Cmax,"Observed Cmax, after i.m. and s.c. administration, was 43 IU/L with median tmax of 9 hours (i.m.) and 5 hours (s.c.).",Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496328/),[iu] / [l],43,1559,DB00644,Gonadorelin
,9496328,tmax,"Observed Cmax, after i.m. and s.c. administration, was 43 IU/L with median tmax of 9 hours (i.m.) and 5 hours (s.c.).",Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496328/),h,9,1560,DB00644,Gonadorelin
,9496328,tmax,"Observed Cmax, after i.m. and s.c. administration, was 43 IU/L with median tmax of 9 hours (i.m.) and 5 hours (s.c.).",Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496328/),h,5,1561,DB00644,Gonadorelin
,9496328,Bioavailability,Bioavailability was 0.54 (i.m.) and 0.56 (s.c.).,Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496328/),,0.54,1562,DB00644,Gonadorelin
,9496328,Bioavailability,Bioavailability was 0.54 (i.m.) and 0.56 (s.c.).,Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496328/),,0.56,1563,DB00644,Gonadorelin
,9496328,terminal half-life,The terminal half-life of recombinant human LH is around 12 hours and is slightly prolonged after extravascular administration.,Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496328/),h,12,1564,DB00644,Gonadorelin
,16223868,affinities,All five analogs bound to guinea pig progesterone binding globulin with relatively high affinities (264-1020 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,264-1020,4000,DB00644,Gonadorelin
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,15,4001,DB00644,Gonadorelin
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,7,4002,DB00644,Gonadorelin
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,4,4003,DB00644,Gonadorelin
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,26,4004,DB00644,Gonadorelin
,9496329,accumulation ratio,"After daily administration, the mean accumulation ratio was 1.6 for LH and 2.9 for FSH, with absorption and terminal phase half-life estimates of 4 and 11 hours for LH and 8 and 16 hours for FSH, respectively.",Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496329/),,1.6,8301,DB00644,Gonadorelin
,9496329,accumulation ratio,"After daily administration, the mean accumulation ratio was 1.6 for LH and 2.9 for FSH, with absorption and terminal phase half-life estimates of 4 and 11 hours for LH and 8 and 16 hours for FSH, respectively.",Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496329/),,2.9,8302,DB00644,Gonadorelin
,9496329,absorption,"After daily administration, the mean accumulation ratio was 1.6 for LH and 2.9 for FSH, with absorption and terminal phase half-life estimates of 4 and 11 hours for LH and 8 and 16 hours for FSH, respectively.",Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496329/),h,4,8303,DB00644,Gonadorelin
,9496329,absorption,"After daily administration, the mean accumulation ratio was 1.6 for LH and 2.9 for FSH, with absorption and terminal phase half-life estimates of 4 and 11 hours for LH and 8 and 16 hours for FSH, respectively.",Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496329/),h,11,8304,DB00644,Gonadorelin
,9496329,terminal phase half-life,"After daily administration, the mean accumulation ratio was 1.6 for LH and 2.9 for FSH, with absorption and terminal phase half-life estimates of 4 and 11 hours for LH and 8 and 16 hours for FSH, respectively.",Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496329/),h,11,8305,DB00644,Gonadorelin
,9496329,terminal phase half-life,"After daily administration, the mean accumulation ratio was 1.6 for LH and 2.9 for FSH, with absorption and terminal phase half-life estimates of 4 and 11 hours for LH and 8 and 16 hours for FSH, respectively.",Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496329/),h,8,8306,DB00644,Gonadorelin
,9496329,terminal phase half-life,"After daily administration, the mean accumulation ratio was 1.6 for LH and 2.9 for FSH, with absorption and terminal phase half-life estimates of 4 and 11 hours for LH and 8 and 16 hours for FSH, respectively.",Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496329/),h,16,8307,DB00644,Gonadorelin
,3539642,peak levels,"LH-RH peak levels varied, in a dose-dependent way, between 119 +/- 16 and 517 +/- 70 ng/l.",Pharmacokinetics of intravenous luteinizing hormone-releasing hormone administration in men: effects of various dosages. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3539642/),[ng] / [l],119,8755,DB00644,Gonadorelin
,3539642,peak levels,"LH-RH peak levels varied, in a dose-dependent way, between 119 +/- 16 and 517 +/- 70 ng/l.",Pharmacokinetics of intravenous luteinizing hormone-releasing hormone administration in men: effects of various dosages. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3539642/),[ng] / [l],517,8756,DB00644,Gonadorelin
,3539642,half-lives,"Peak values were all reached between 1 and 3 minutes after injection, and elimination occurred rapidly, with half-lives between 2.6 +/- 0.4 and 5.2 +/- 1.0 minutes.",Pharmacokinetics of intravenous luteinizing hormone-releasing hormone administration in men: effects of various dosages. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3539642/),min,2.6,8757,DB00644,Gonadorelin
,3539642,half-lives,"Peak values were all reached between 1 and 3 minutes after injection, and elimination occurred rapidly, with half-lives between 2.6 +/- 0.4 and 5.2 +/- 1.0 minutes.",Pharmacokinetics of intravenous luteinizing hormone-releasing hormone administration in men: effects of various dosages. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3539642/),min,5.2,8758,DB00644,Gonadorelin
,33347565,apparent half-life (t1/2),"The median Tmax of TU2670 occurred 0.75 to 1.00 hours after dosing, and concentrations then declined, with a mean apparent half-life (t1/2) of 3.0 to 5.9 hours.","First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33347565/),h,3.0 to 5.9,9661,DB00644,Gonadorelin
,33347565,AUClast,AUClast (17.7-417.9 ng·h/mL) and Cmax (8.1-95.4 ng/mL) increased in a dose-dependent manner.,"First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33347565/),[h·ng] / [ml],17.7-417.9,9662,DB00644,Gonadorelin
,33347565,Cmax,AUClast (17.7-417.9 ng·h/mL) and Cmax (8.1-95.4 ng/mL) increased in a dose-dependent manner.,"First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33347565/),[ng] / [ml],8.1-95.4,9663,DB00644,Gonadorelin
,15198506,liver/tumor uptake ratio,"The liver/tumor uptake ratio of free drug, conventional (LL), and sterically stabilized liposomes (SLL5000 and SLL2000) was found to be 20, 7.99, 1.63, and 1.23, respectively, which showed the increased accumulation of sterically stabilized liposomes in tumor compared with the free drug and conventional liposomes at 24 hours postinjection.","Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198506/),,20,14518,DB00644,Gonadorelin
,15198506,liver/tumor uptake ratio,"The liver/tumor uptake ratio of free drug, conventional (LL), and sterically stabilized liposomes (SLL5000 and SLL2000) was found to be 20, 7.99, 1.63, and 1.23, respectively, which showed the increased accumulation of sterically stabilized liposomes in tumor compared with the free drug and conventional liposomes at 24 hours postinjection.","Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198506/),,7.99,14519,DB00644,Gonadorelin
,15198506,liver/tumor uptake ratio,"The liver/tumor uptake ratio of free drug, conventional (LL), and sterically stabilized liposomes (SLL5000 and SLL2000) was found to be 20, 7.99, 1.63, and 1.23, respectively, which showed the increased accumulation of sterically stabilized liposomes in tumor compared with the free drug and conventional liposomes at 24 hours postinjection.","Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198506/),,1.63,14520,DB00644,Gonadorelin
,15198506,liver/tumor uptake ratio,"The liver/tumor uptake ratio of free drug, conventional (LL), and sterically stabilized liposomes (SLL5000 and SLL2000) was found to be 20, 7.99, 1.63, and 1.23, respectively, which showed the increased accumulation of sterically stabilized liposomes in tumor compared with the free drug and conventional liposomes at 24 hours postinjection.","Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198506/),,1.23,14521,DB00644,Gonadorelin
,3157512,half-time of disappearance from the serum,"The assay appears specific for intact 118630 which, after subcutaneous administration of 250 micrograms, has a half-time of disappearance from the serum of 4.9 +/- 0.4 h and a volume of distribution of 13.7 +/- 0.8 litres.",A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu)6 AZA Gly10 GnRH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157512/),h,4.9,17284,DB00644,Gonadorelin
,3157512,volume of distribution,"The assay appears specific for intact 118630 which, after subcutaneous administration of 250 micrograms, has a half-time of disappearance from the serum of 4.9 +/- 0.4 h and a volume of distribution of 13.7 +/- 0.8 litres.",A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu)6 AZA Gly10 GnRH. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3157512/),l,13.7,17285,DB00644,Gonadorelin
,30653693,Relative recoveries,"Relative recoveries of leuprolide and triptorelin were found to be 80.3 and 75.5%, respectively.",Quantification of controlled release leuprolide and triptorelin in rabbit plasma using electromembrane extraction coupled with HPLC-UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30653693/),%,80.3,19485,DB00644,Gonadorelin
,30653693,Relative recoveries,"Relative recoveries of leuprolide and triptorelin were found to be 80.3 and 75.5%, respectively.",Quantification of controlled release leuprolide and triptorelin in rabbit plasma using electromembrane extraction coupled with HPLC-UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30653693/),%,75.5,19486,DB00644,Gonadorelin
,30653693,Limits,"Limits of quantification and detection for both peptides were found to be 0.5 and 0.15 ng/mL, respectively.",Quantification of controlled release leuprolide and triptorelin in rabbit plasma using electromembrane extraction coupled with HPLC-UV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30653693/),[ng] / [ml],0.5,19487,DB00644,Gonadorelin
,9354307,Cmax,The maximum concentrations of triptorelin were found to be similar for all four study groups (geometric mean Cmax between 41.6 mg ml(-1) and 53.9 mg ml(-1)).,Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),[mg] / [ml],41.6,19975,DB00644,Gonadorelin
,9354307,Cmax,The maximum concentrations of triptorelin were found to be similar for all four study groups (geometric mean Cmax between 41.6 mg ml(-1) and 53.9 mg ml(-1)).,Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),[mg] / [ml],53.9,19976,DB00644,Gonadorelin
,9354307,CLtot,"The total clearance of triptorelin decreased with increasing renal impairment, and was even lower in patients with hepatic insufficiency (geometric mean CLtot: 210 ml min(-1), 113 ml min(-1), 86.8 ml min(-1) and 57.3 ml min(-1) for Groups I, II, III and IV, respectively).",Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),[ml] / [min],210,19977,DB00644,Gonadorelin
,9354307,CLtot,"The total clearance of triptorelin decreased with increasing renal impairment, and was even lower in patients with hepatic insufficiency (geometric mean CLtot: 210 ml min(-1), 113 ml min(-1), 86.8 ml min(-1) and 57.3 ml min(-1) for Groups I, II, III and IV, respectively).",Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),[ml] / [min],113,19978,DB00644,Gonadorelin
,9354307,CLtot,"The total clearance of triptorelin decreased with increasing renal impairment, and was even lower in patients with hepatic insufficiency (geometric mean CLtot: 210 ml min(-1), 113 ml min(-1), 86.8 ml min(-1) and 57.3 ml min(-1) for Groups I, II, III and IV, respectively).",Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),[ml] / [min],86.8,19979,DB00644,Gonadorelin
,9354307,CLtot,"The total clearance of triptorelin decreased with increasing renal impairment, and was even lower in patients with hepatic insufficiency (geometric mean CLtot: 210 ml min(-1), 113 ml min(-1), 86.8 ml min(-1) and 57.3 ml min(-1) for Groups I, II, III and IV, respectively).",Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),[ml] / [min],57.3,19980,DB00644,Gonadorelin
,9354307,"t(1/2, z)","The elimination half-life for patients with hepatic impairment was similar to that of patients with renal impairment (geometric mean t(1/2, z): 6.6 h, 7.7 h and 7.6 h for Groups II, III and IV, respectively), but significantly longer than in healthy volunteers (2.8 h for Group I).",Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),h,6.6,19981,DB00644,Gonadorelin
,9354307,"t(1/2, z)","The elimination half-life for patients with hepatic impairment was similar to that of patients with renal impairment (geometric mean t(1/2, z): 6.6 h, 7.7 h and 7.6 h for Groups II, III and IV, respectively), but significantly longer than in healthy volunteers (2.8 h for Group I).",Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),h,7.7,19982,DB00644,Gonadorelin
,9354307,"t(1/2, z)","The elimination half-life for patients with hepatic impairment was similar to that of patients with renal impairment (geometric mean t(1/2, z): 6.6 h, 7.7 h and 7.6 h for Groups II, III and IV, respectively), but significantly longer than in healthy volunteers (2.8 h for Group I).",Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),h,7.6,19983,DB00644,Gonadorelin
,9354307,"t(1/2, z)","The elimination half-life for patients with hepatic impairment was similar to that of patients with renal impairment (geometric mean t(1/2, z): 6.6 h, 7.7 h and 7.6 h for Groups II, III and IV, respectively), but significantly longer than in healthy volunteers (2.8 h for Group I).",Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),h,2.8,19984,DB00644,Gonadorelin
,9354307,distribution half-lives,"The first and second distribution half-lives were similar for the four groups studied, with geometric mean distribution half-lives of about 0.1 h (6 min) and 0.75 h (45 min), respectively.",Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),h,0.1,19985,DB00644,Gonadorelin
,9354307,distribution half-lives,"The first and second distribution half-lives were similar for the four groups studied, with geometric mean distribution half-lives of about 0.1 h (6 min) and 0.75 h (45 min), respectively.",Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354307/),h,0.75,19986,DB00644,Gonadorelin
,24418777,binding affinities,"Compared to DOTA-Ahx-(D-Lys(6)-GnRH1) (36.1 nM), the introduction of D-Phe improved the GnRH receptor binding affinities of DOTA-D-Phe-Ahx-(D-Lys(6)-GnRH) (16.3 nM) and DOTA-Ahx-D-Phe-(D-Lys(6)-GnRH) (7.6 nM).",Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418777/),nM,16.3,20098,DB00644,Gonadorelin
,24418777,binding affinities,"Compared to DOTA-Ahx-(D-Lys(6)-GnRH1) (36.1 nM), the introduction of D-Phe improved the GnRH receptor binding affinities of DOTA-D-Phe-Ahx-(D-Lys(6)-GnRH) (16.3 nM) and DOTA-Ahx-D-Phe-(D-Lys(6)-GnRH) (7.6 nM).",Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418777/),nM,7.6,20099,DB00644,Gonadorelin
above,25005890,recovery,The recovery was above 80% with low matrix effects.,Determination of a deuterohemin-peptide conjugate in rat plasma by liquid chromatography-tandem mass spectrometry and application to a preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25005890/),%,80,28213,DB00644,Gonadorelin
,1385467,serum half-life,"The mean serum half-life values based on the terminal portion of the disappearance curves were 22.8 +/- 2.5 and 26.9 +/- 1.0 h, respectively, after 3- and 6-mg s.c. doses.",Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1385467/),h,22.8,31754,DB00644,Gonadorelin
,1385467,serum half-life,"The mean serum half-life values based on the terminal portion of the disappearance curves were 22.8 +/- 2.5 and 26.9 +/- 1.0 h, respectively, after 3- and 6-mg s.c. doses.",Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1385467/),h,26.9,31755,DB00644,Gonadorelin
,22421322,zeta potential,"The thiolated (chitosan-TGA) NPs had a mean size of 252 ± 82 nm, a zeta potential of +10.9 ± 4 mV, and payload of leuprolide was 12 ± 2.8.",Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22421322/),m,10.9,32560,DB00644,Gonadorelin
,22421322,relative nasal bioavailability,The relative nasal bioavailability (versus s.c. injection) of leuprolide thiolated NPs calculated on the basis of AUC((0-6)) was about 19.6% as compared to leuprolide solution 2.8%.,Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22421322/),%,19.6,32561,DB00644,Gonadorelin
,22421322,relative nasal bioavailability,The relative nasal bioavailability (versus s.c. injection) of leuprolide thiolated NPs calculated on the basis of AUC((0-6)) was about 19.6% as compared to leuprolide solution 2.8%.,Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22421322/),%,2.8,32562,DB00644,Gonadorelin
,3090003,half-life,"Passive immunization of chronically ovariectomized gilts against gonadotropin releasing hormone (GnRH) resulted in an abrupt cessation of pulsatile secretion of luteinizing hormone (LH) accompanied by clearance from serum with a mean half-life of 30.9 +/- 2.3 (mean +/- SE) and 918 +/- 200 min for the first and second compartment, respectively.",Clearance rate of luteinizing hormone and follicle stimulating hormone from peripheral circulation in the pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3090003/),min,30.9,43800,DB00644,Gonadorelin
,3090003,half-life,"Passive immunization of chronically ovariectomized gilts against gonadotropin releasing hormone (GnRH) resulted in an abrupt cessation of pulsatile secretion of luteinizing hormone (LH) accompanied by clearance from serum with a mean half-life of 30.9 +/- 2.3 (mean +/- SE) and 918 +/- 200 min for the first and second compartment, respectively.",Clearance rate of luteinizing hormone and follicle stimulating hormone from peripheral circulation in the pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3090003/),min,918,43801,DB00644,Gonadorelin
,3090003,half-life,Serum follicle stimulating hormone (FSH) was unaffected immediately by passive immunization against GnRH and declined slowly with a half-life of 4.9 +/- .7 d.,Clearance rate of luteinizing hormone and follicle stimulating hormone from peripheral circulation in the pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3090003/),d,4.9,43802,DB00644,Gonadorelin
,3090003,half-lives for the first compartment,"After LH and FSH had declined to basal levels in passively immunized gilts, injection of a bolus of LH and FSH resulted in peak values within 5 min and depletion curves with half-lives for the first compartment of 28.0 +/- 1.3 and 36.4 +/- 2.6 min and for the second compartment of 679 +/- 98 and 1,230 +/- 54 min, for LH and FSH respectively.",Clearance rate of luteinizing hormone and follicle stimulating hormone from peripheral circulation in the pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3090003/),min,28.0,43803,DB00644,Gonadorelin
,3090003,half-lives for the first compartment,"After LH and FSH had declined to basal levels in passively immunized gilts, injection of a bolus of LH and FSH resulted in peak values within 5 min and depletion curves with half-lives for the first compartment of 28.0 +/- 1.3 and 36.4 +/- 2.6 min and for the second compartment of 679 +/- 98 and 1,230 +/- 54 min, for LH and FSH respectively.",Clearance rate of luteinizing hormone and follicle stimulating hormone from peripheral circulation in the pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3090003/),min,36.4,43804,DB00644,Gonadorelin
,3090003,half-lives for the first compartment,"After LH and FSH had declined to basal levels in passively immunized gilts, injection of a bolus of LH and FSH resulted in peak values within 5 min and depletion curves with half-lives for the first compartment of 28.0 +/- 1.3 and 36.4 +/- 2.6 min and for the second compartment of 679 +/- 98 and 1,230 +/- 54 min, for LH and FSH respectively.",Clearance rate of luteinizing hormone and follicle stimulating hormone from peripheral circulation in the pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3090003/),min,679,43805,DB00644,Gonadorelin
,3090003,half-lives for the first compartment,"After LH and FSH had declined to basal levels in passively immunized gilts, injection of a bolus of LH and FSH resulted in peak values within 5 min and depletion curves with half-lives for the first compartment of 28.0 +/- 1.3 and 36.4 +/- 2.6 min and for the second compartment of 679 +/- 98 and 1,230 +/- 54 min, for LH and FSH respectively.",Clearance rate of luteinizing hormone and follicle stimulating hormone from peripheral circulation in the pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3090003/),min,"1,230",43806,DB00644,Gonadorelin
,10425368,permeability coefficients,"In vitro permeability of leuprolide in the rabbit GI tract was performed using a side-by-side diffusion apparatus and the permeability coefficients in the jejunum, ileum and colon were 0.27x10(-7), 2.96x10(-7) and 7.85x10(-7)cm/s, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),[cm] / [s],0.27x10(-7),45316,DB00644,Gonadorelin
,10425368,permeability coefficients,"In vitro permeability of leuprolide in the rabbit GI tract was performed using a side-by-side diffusion apparatus and the permeability coefficients in the jejunum, ileum and colon were 0.27x10(-7), 2.96x10(-7) and 7.85x10(-7)cm/s, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),[cm] / [s],2.96x10(-7),45317,DB00644,Gonadorelin
,10425368,permeability coefficients,"In vitro permeability of leuprolide in the rabbit GI tract was performed using a side-by-side diffusion apparatus and the permeability coefficients in the jejunum, ileum and colon were 0.27x10(-7), 2.96x10(-7) and 7.85x10(-7)cm/s, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),[cm] / [s],7.85x10(-7),45318,DB00644,Gonadorelin
,10425368,bioavailabilities,"Using an intestine loop model in anesthetized rats, bioavailabilities of leuprolide in the jejunum, ileum and colon were 1.28, 5.62 and 9.59%, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,1.28,45319,DB00644,Gonadorelin
,10425368,bioavailabilities,"Using an intestine loop model in anesthetized rats, bioavailabilities of leuprolide in the jejunum, ileum and colon were 1.28, 5.62 and 9.59%, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,5.62,45320,DB00644,Gonadorelin
,10425368,bioavailabilities,"Using an intestine loop model in anesthetized rats, bioavailabilities of leuprolide in the jejunum, ileum and colon were 1.28, 5.62 and 9.59%, respectively.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,9.59,45321,DB00644,Gonadorelin
,10425368,Drug recovery,"Drug recovery from the loop 5 h after dosing was 10.7% in jejunum, 24.5% in ileum and 40.7% in colon.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,10.7,45322,DB00644,Gonadorelin
,10425368,Drug recovery,"Drug recovery from the loop 5 h after dosing was 10.7% in jejunum, 24.5% in ileum and 40.7% in colon.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,24.5,45323,DB00644,Gonadorelin
,10425368,Drug recovery,"Drug recovery from the loop 5 h after dosing was 10.7% in jejunum, 24.5% in ileum and 40.7% in colon.",Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,40.7,45324,DB00644,Gonadorelin
less,10425368,bioavailability,Additional in vivo studies using conscious rats showed that the bioavailability of leuprolide was less than 1% for both ileal and colonic administration.,Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10425368/),%,1,45325,DB00644,Gonadorelin
,20435244,AUC(0-t),"Values for AUC(0-t) calculated from day 0 to day 28, days 28 to 56, and days 56 to 84 were 25,976.5 (7892.0), 30,685.5 (9348.4), and 31,030.9 (10,745.0) pg/mL per day, respectively.","Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435244/),[pg] / [d·ml],"25,976.5",48323,DB00644,Gonadorelin
,20435244,AUC(0-t),"Values for AUC(0-t) calculated from day 0 to day 28, days 28 to 56, and days 56 to 84 were 25,976.5 (7892.0), 30,685.5 (9348.4), and 31,030.9 (10,745.0) pg/mL per day, respectively.","Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435244/),[pg] / [d·ml],"30,685.5",48324,DB00644,Gonadorelin
,20435244,AUC(0-t),"Values for AUC(0-t) calculated from day 0 to day 28, days 28 to 56, and days 56 to 84 were 25,976.5 (7892.0), 30,685.5 (9348.4), and 31,030.9 (10,745.0) pg/mL per day, respectively.","Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435244/),[pg] / [d·ml],"31,030.9",48325,DB00644,Gonadorelin
,18330698,AUC,"Mean plasma estrogen levels (AUC(day 36-57)) were significantly lower for subjects who received T + EX than for subjects who received T alone (20.6 vs. 54.0 pg d/ml [-62%; P < 0.05], and 38.9 vs. 198.0 pg d/ml [-80%; P < 0.01] for E(2) and E(1), respectively).",Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330698/),[d·pg] / [ml],20.6,51898,DB00644,Gonadorelin
,18330698,AUC,"Mean plasma estrogen levels (AUC(day 36-57)) were significantly lower for subjects who received T + EX than for subjects who received T alone (20.6 vs. 54.0 pg d/ml [-62%; P < 0.05], and 38.9 vs. 198.0 pg d/ml [-80%; P < 0.01] for E(2) and E(1), respectively).",Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330698/),[d·pg] / [ml],54.0,51899,DB00644,Gonadorelin
,18330698,AUC,"Mean plasma estrogen levels (AUC(day 36-57)) were significantly lower for subjects who received T + EX than for subjects who received T alone (20.6 vs. 54.0 pg d/ml [-62%; P < 0.05], and 38.9 vs. 198.0 pg d/ml [-80%; P < 0.01] for E(2) and E(1), respectively).",Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330698/),[d·pg] / [ml],38.9,51900,DB00644,Gonadorelin
,18330698,AUC,"Mean plasma estrogen levels (AUC(day 36-57)) were significantly lower for subjects who received T + EX than for subjects who received T alone (20.6 vs. 54.0 pg d/ml [-62%; P < 0.05], and 38.9 vs. 198.0 pg d/ml [-80%; P < 0.01] for E(2) and E(1), respectively).",Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18330698/),[d·pg] / [ml],198.0,51901,DB00644,Gonadorelin
,7937547,Tmax,Absorption from the lung after instillation was slow (Tmax = 6.5 +/- 3.6 h) with a relative bioavailability of 29 +/- 10%.,Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937547/),h,6.5,56214,DB00644,Gonadorelin
,7937547,relative bioavailability,Absorption from the lung after instillation was slow (Tmax = 6.5 +/- 3.6 h) with a relative bioavailability of 29 +/- 10%.,Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937547/),%,29,56215,DB00644,Gonadorelin
,31257725,flow rate,"After sample preparation by protein precipitation followed by reversed phase solid phase extraction, alarelin and triptorelin (internal standard) were chromatographed on an Ascentis® Express C18 column (50 mm × 4.6 mm, 2.7 µm) using gradient elution with 0.1% formic acid in water and acetonitrile at a flow rate of 1 mL/min.",Liquid chromatography tandem mass spectrometry with triple stage fragmentation for highly selective analysis and pharmacokinetics of alarelin in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257725/),[ml] / [min],1,59592,DB00644,Gonadorelin
,2513176,area under the serum concentration-time curve from zero to 35 days (AUC0-35 days),A significant dose-dependent increase in the area under the serum concentration-time curve from zero to 35 days (AUC0-35 days) from 541.7 to 1653.9 ng/ml.h was also noted (p less than 0.01).,"Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2513176/),[ng] / [h·ml],541.7 to 1653.9,60280,DB00644,Gonadorelin
,24981575,IC50,"ASP9521 inhibited conversion of AD into T by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L; IC50,monkey: 49 nmol/L).","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),[nM] / [l],11,61031,DB00644,Gonadorelin
,24981575,IC50,"ASP9521 inhibited conversion of AD into T by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L; IC50,monkey: 49 nmol/L).","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),[nM] / [l],49,61032,DB00644,Gonadorelin
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,35,61033,DB00644,Gonadorelin
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,78,61034,DB00644,Gonadorelin
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,58,61035,DB00644,Gonadorelin
,1686228,CLs,"Plasma pharmacokinetics after iv administration were: CLs = 2.5 ml/min/kg, Vd beta = 0.29 liter/kg, t1/2 = 1.4 hr (rats), and CLs = 0.8 ml/min/kg, Vd beta = 0.32 liter/kg, t1/2 = 5.1 hr (monkeys).","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),[ml] / [kg·min],2.5,61174,DB00644,Gonadorelin
,1686228,Vd beta,"Plasma pharmacokinetics after iv administration were: CLs = 2.5 ml/min/kg, Vd beta = 0.29 liter/kg, t1/2 = 1.4 hr (rats), and CLs = 0.8 ml/min/kg, Vd beta = 0.32 liter/kg, t1/2 = 5.1 hr (monkeys).","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),[l] / [kg],0.29,61175,DB00644,Gonadorelin
,1686228,t1/2,"Plasma pharmacokinetics after iv administration were: CLs = 2.5 ml/min/kg, Vd beta = 0.29 liter/kg, t1/2 = 1.4 hr (rats), and CLs = 0.8 ml/min/kg, Vd beta = 0.32 liter/kg, t1/2 = 5.1 hr (monkeys).","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),h,1.4,61176,DB00644,Gonadorelin
,1686228,CLs,"Plasma pharmacokinetics after iv administration were: CLs = 2.5 ml/min/kg, Vd beta = 0.29 liter/kg, t1/2 = 1.4 hr (rats), and CLs = 0.8 ml/min/kg, Vd beta = 0.32 liter/kg, t1/2 = 5.1 hr (monkeys).","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),[ml] / [kg·min],0.8,61177,DB00644,Gonadorelin
,1686228,Vd beta,"Plasma pharmacokinetics after iv administration were: CLs = 2.5 ml/min/kg, Vd beta = 0.29 liter/kg, t1/2 = 1.4 hr (rats), and CLs = 0.8 ml/min/kg, Vd beta = 0.32 liter/kg, t1/2 = 5.1 hr (monkeys).","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),[l] / [kg],0.32,61178,DB00644,Gonadorelin
,1686228,t1/2,"Plasma pharmacokinetics after iv administration were: CLs = 2.5 ml/min/kg, Vd beta = 0.29 liter/kg, t1/2 = 1.4 hr (rats), and CLs = 0.8 ml/min/kg, Vd beta = 0.32 liter/kg, t1/2 = 5.1 hr (monkeys).","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),h,5.1,61179,DB00644,Gonadorelin
,1686228,Cmax,"Cmax and Tmax in rats were 0.53 micrograms/ml and 4 hr after the 1 mg/kg sc dose, and were 1.07 micrograms/ml and 12 hr after the 10 mg/kg sc dose.","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),[μg] / [ml],0.53,61180,DB00644,Gonadorelin
,1686228,Cmax,"Cmax and Tmax in rats were 0.53 micrograms/ml and 4 hr after the 1 mg/kg sc dose, and were 1.07 micrograms/ml and 12 hr after the 10 mg/kg sc dose.","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),[μg] / [ml],1.07,61181,DB00644,Gonadorelin
,1686228,Tmax,"Cmax and Tmax in rats were 0.53 micrograms/ml and 4 hr after the 1 mg/kg sc dose, and were 1.07 micrograms/ml and 12 hr after the 10 mg/kg sc dose.","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),h,4,61182,DB00644,Gonadorelin
,1686228,Tmax,"Cmax and Tmax in rats were 0.53 micrograms/ml and 4 hr after the 1 mg/kg sc dose, and were 1.07 micrograms/ml and 12 hr after the 10 mg/kg sc dose.","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),h,12,61183,DB00644,Gonadorelin
,1686228,Apparent plasma disappearance t1/2,"Apparent plasma disappearance t1/2 in rats were 3.6 and 15.2 hr, respectively, after the 1 and 10 mg/kg sc doses.","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),h,3.6,61184,DB00644,Gonadorelin
,1686228,Apparent plasma disappearance t1/2,"Apparent plasma disappearance t1/2 in rats were 3.6 and 15.2 hr, respectively, after the 1 and 10 mg/kg sc doses.","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),h,15.2,61185,DB00644,Gonadorelin
,1686228,Tmax,"In monkeys, Tmax after a 1 mg/kg sc dose was 0.5 hr for three animals but was 24 hr for the fourth animal, although plasma of this monkey contained substantial levels of RS-26306 between 15 min and 24 hr.","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),h,0.5,61186,DB00644,Gonadorelin
,1686228,Tmax,"In monkeys, Tmax after a 1 mg/kg sc dose was 0.5 hr for three animals but was 24 hr for the fourth animal, although plasma of this monkey contained substantial levels of RS-26306 between 15 min and 24 hr.","Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),h,24,61187,DB00644,Gonadorelin
,1686228,Apparent plasma t1/2,Apparent plasma t1/2 in monkeys after a 1 mg/kg sc dose was at least 19 hr.,"Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),h,19,61188,DB00644,Gonadorelin
,1686228,plasma binding,In vitro plasma binding amounted to 82-84%.,"Disposition of RS-26306, a potent luteinizing hormone-releasing hormone antagonist, in monkeys and rats after single intravenous and subcutaneous administration. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686228/),%,82-84,61189,DB00644,Gonadorelin
,6384253,plateau levels,"During the continuous infusions, plateau levels of IR-GnRH between 2 and 6 h were 34% lower with sc delivery (67.5 vs. 102.4 pg/ml), indicating irreversible losses of about one third of GnRH injected sc.",Pharmacokinetics of gonadotropin-releasing hormone: comparison of subcutaneous and intravenous routes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6384253/),[pg] / [ml],67.5,65297,DB00644,Gonadorelin
,6384253,plateau levels,"During the continuous infusions, plateau levels of IR-GnRH between 2 and 6 h were 34% lower with sc delivery (67.5 vs. 102.4 pg/ml), indicating irreversible losses of about one third of GnRH injected sc.",Pharmacokinetics of gonadotropin-releasing hormone: comparison of subcutaneous and intravenous routes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6384253/),[pg] / [ml],102.4,65298,DB00644,Gonadorelin
,24650013,distributional half-life,"The obese group had a significantly decreased distributional half-life of cetrorelix compared with the normal-weight group (8.1 ± 1.6 vs 12.7 ± 6.2 hours, P = .02).",Evidence of GnRH antagonist escape in obese women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24650013/),h,8.1,65939,DB00644,Gonadorelin
,24650013,distributional half-life,"The obese group had a significantly decreased distributional half-life of cetrorelix compared with the normal-weight group (8.1 ± 1.6 vs 12.7 ± 6.2 hours, P = .02).",Evidence of GnRH antagonist escape in obese women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24650013/),h,12.7,65940,DB00644,Gonadorelin
,24650013,clearance,"The obese group exhibited increased clearance of cetrorelix compared with the normal-weight group (25.8 ± 6.8 vs 20.1 ± 8.3 L/h, P = .058).",Evidence of GnRH antagonist escape in obese women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24650013/),[l] / [h],25.8,65941,DB00644,Gonadorelin
,24650013,clearance,"The obese group exhibited increased clearance of cetrorelix compared with the normal-weight group (25.8 ± 6.8 vs 20.1 ± 8.3 L/h, P = .058).",Evidence of GnRH antagonist escape in obese women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24650013/),[l] / [h],20.1,65942,DB00644,Gonadorelin
over,24911546,extract recoveries,The average extract recoveries in the rat plasma were all over 72%.,Simultaneous determination of five novel luteinizing hormone-releasing hormone antagonists by LC-MS and pharmacokinetics in rats following cassette dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24911546/),%,72,68942,DB00644,Gonadorelin
,11474780,bioavailabilities,"Comparing the plasma concentration after intratracheal aerosolization with data of intravenous administration, the mean calculated bioavailabilities for the four formulations using the corrected dose (delivered--exhaled amount) were between 48.4 +/- 27.0% and 77.4 +/- 44.0%.",Systemic delivery of cetrorelix to rats by a new aerosol delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474780/),%,48.4,71549,DB00644,Gonadorelin
,11474780,bioavailabilities,"Comparing the plasma concentration after intratracheal aerosolization with data of intravenous administration, the mean calculated bioavailabilities for the four formulations using the corrected dose (delivered--exhaled amount) were between 48.4 +/- 27.0% and 77.4 +/- 44.0%.",Systemic delivery of cetrorelix to rats by a new aerosol delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474780/),%,77.4,71550,DB00644,Gonadorelin
,12211225,Duration of,"Duration of atleasthalf-maximum suppression was after the first dose median of 82 hours and after the fourth dose median of 122 hours, respectively.",Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12211225/),h,82,73287,DB00644,Gonadorelin
,12211225,Duration of,"Duration of atleasthalf-maximum suppression was after the first dose median of 82 hours and after the fourth dose median of 122 hours, respectively.",Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12211225/),h,122,73288,DB00644,Gonadorelin
,12211225,maximum suppression,"Duration of atleasthalf-maximum suppression was after the first dose median of 82 hours and after the fourth dose median of 122 hours, respectively.",Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12211225/),h,82,73289,DB00644,Gonadorelin
,12211225,maximum suppression,"Duration of atleasthalf-maximum suppression was after the first dose median of 82 hours and after the fourth dose median of 122 hours, respectively.",Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12211225/),h,122,73290,DB00644,Gonadorelin
,16400081,area-under-the-curve,"In the fasting state, 24-hour area-under-the-curve of serum T after oral T administration was significantly greater with coadministration of either D or F compared with T-alone (126 +/- 36 nmol-h/L [T-alone] vs 287 +/- 98 nmol-h/L [T + F] vs 236 +/- 82 nmol-h/L [T + D]; P < .05 for T + F and T + D vs T-alone).",Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400081/),[nmol-h] / [l],126,79198,DB00644,Gonadorelin
,16400081,area-under-the-curve,"In the fasting state, 24-hour area-under-the-curve of serum T after oral T administration was significantly greater with coadministration of either D or F compared with T-alone (126 +/- 36 nmol-h/L [T-alone] vs 287 +/- 98 nmol-h/L [T + F] vs 236 +/- 82 nmol-h/L [T + D]; P < .05 for T + F and T + D vs T-alone).",Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400081/),[nmol-h] / [l],287,79199,DB00644,Gonadorelin
,16400081,area-under-the-curve,"In the fasting state, 24-hour area-under-the-curve of serum T after oral T administration was significantly greater with coadministration of either D or F compared with T-alone (126 +/- 36 nmol-h/L [T-alone] vs 287 +/- 98 nmol-h/L [T + F] vs 236 +/- 82 nmol-h/L [T + D]; P < .05 for T + F and T + D vs T-alone).",Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400081/),[nmol-h] / [l],236,79200,DB00644,Gonadorelin
,2126737,fractional excretion,The release rate is monitored by urinary buserelin excretion (fractional excretion of 30% of the daily dose).,Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126737/),%,30,79985,DB00644,Gonadorelin
,2126737,half-life,"After high dose injection, buserelin has a half-life of 80 min, therapeutic plasma concentrations are maintained for 8-12 h.",Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126737/),min,80,79986,DB00644,Gonadorelin
,2126737,excretion,"In endometriosis and leiomyoma, the minimum release rate (urinary buserelin) required for maintenance of steroid suppression was established (buserelin excretion of about 0.5 microgram/g creatinine).",Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126737/),[μg] / [g],0.5,79987,DB00644,Gonadorelin
,17169119,LD50,"In intravenous single-dose studies in mice, the LD50 was 731.26 microg/kg and 676.03 microg/kg in male and female mice respectively.",A recombinant protein LHRH-PE40 for tumour therapy: preclinical safety studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17169119/),[μg] / [kg],731.26,80845,DB00644,Gonadorelin
,17169119,LD50,"In intravenous single-dose studies in mice, the LD50 was 731.26 microg/kg and 676.03 microg/kg in male and female mice respectively.",A recombinant protein LHRH-PE40 for tumour therapy: preclinical safety studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17169119/),[μg] / [kg],676.03,80846,DB00644,Gonadorelin
,8865318,absolute bioavailability,The absolute bioavailability of the peptide after buccal delivery for 4 hours could be increased from 1.0 +/- 0.3 to 5.3 +/- 1.1% (mean +/- SD.) by co-administration of 10 mM GDC (0.45% w/v)).,In vivo buccal delivery of the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865318/),%,1.0,81837,DB00644,Gonadorelin
,8865318,absolute bioavailability,The absolute bioavailability of the peptide after buccal delivery for 4 hours could be increased from 1.0 +/- 0.3 to 5.3 +/- 1.1% (mean +/- SD.) by co-administration of 10 mM GDC (0.45% w/v)).,In vivo buccal delivery of the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865318/),%,5.3,81838,DB00644,Gonadorelin
<,24756362,peak-stimulated LH concentrations,The probability of LH suppression (peak-stimulated LH concentrations <4 mIU/mL) exposure-response relationship was modelled using repeated measures logistic regression.,Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24756362/),[miu] / [ml],4,84851,DB00644,Gonadorelin
,2970910,time to reach peak concentration,"Nafarelin, a potent gonadotropin-releasing hormone (GnRH) agonist, was absorbed rapidly into systemic circulation (time to reach peak concentration, 20 to 40 minutes) after intranasal but not after sublingual or vaginal administration.","Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2970910/),min,20 to 40,90804,DB00644,Gonadorelin
,2970910,Serum elimination half-life,Serum elimination half-life was about 2 hours.,"Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2970910/),h,2,90805,DB00644,Gonadorelin
,2970910,Bioavailability,Bioavailability of this nasal formulation relative to a single subcutaneous dose averaged 21%.,"Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2970910/),%,21,90806,DB00644,Gonadorelin
,15579744,maximum concentration,Serum acyline levels peaked 90 min after the injection of 300 microg/kg acyline to a maximum concentration of 112.4 +/- 18 ng/ml (n = 7; t(1/2) = 4.9 d).,A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579744/),[ng] / [ml],112.4,91315,DB00644,Gonadorelin
,15579744,t(1/2),Serum acyline levels peaked 90 min after the injection of 300 microg/kg acyline to a maximum concentration of 112.4 +/- 18 ng/ml (n = 7; t(1/2) = 4.9 d).,A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579744/),d,4.9,91316,DB00644,Gonadorelin
,15579744,T,"Injections of 75 microg/kg acyline every 2 d for five doses suppressed gonadotropins for more than 20 d (nadir T, 1.06 +/- 0.17 nmol/liter; P < 0.05 compared with baseline).",A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579744/),[nM] / [l],1.06,91317,DB00644,Gonadorelin
,10926349,elimination half-life (t1/2beta),"When administered as a solution, goserelin is rapidly absorbed and eliminated from serum with a mean elimination half-life (t1/2beta) of 4.2 hours in males and 2.3 hours in females.",Clinical pharmacokinetics of goserelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926349/),h,4.2,93314,DB00644,Gonadorelin
,10926349,elimination half-life (t1/2beta),"When administered as a solution, goserelin is rapidly absorbed and eliminated from serum with a mean elimination half-life (t1/2beta) of 4.2 hours in males and 2.3 hours in females.",Clinical pharmacokinetics of goserelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926349/),h,2.3,93315,DB00644,Gonadorelin
,10926349,t1/2beta,"Its pharmacokinetics are unaffected by hepatic impairment, but the mean t1/2beta increases to 12.1 hours in patients with severe renal impairment.",Clinical pharmacokinetics of goserelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926349/),h,12.1,93316,DB00644,Gonadorelin
,16239357,concentrations,"At the end of 52 weeks, mean histrelin concentrations were 0.128 +/- 0.0652 ng/mL.",An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239357/),ng,0.128,94268,DB00644,Gonadorelin
,21277965,% recoveries,"LA was stable in the patch, % recoveries for 3 months were 102.2±1.9-95.3±1.9%.",Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),%,102.2,95351,DB00644,Gonadorelin
,21277965,% recoveries,"LA was stable in the patch, % recoveries for 3 months were 102.2±1.9-95.3±1.9%.",Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),%,95.3,95352,DB00644,Gonadorelin
,21277965,C(max),"Plasma LA concentrations increased immediately after administration, and reached to the maximum level at 15 min, where C(max) were 6.0±0.7 and 16.4±0.9 μg/ml, respectively.",Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),[μg] / [ml],6.0,95353,DB00644,Gonadorelin
,21277965,C(max),"Plasma LA concentrations increased immediately after administration, and reached to the maximum level at 15 min, where C(max) were 6.0±0.7 and 16.4±0.9 μg/ml, respectively.",Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),[μg] / [ml],16.4,95354,DB00644,Gonadorelin
,21277965,AUC,The AUC were 5.8±0.8 and 14.5±0.4 μg h/ml and BA were 33.8±4.3% and 31.7±0.8%.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),[h·μg] / [ml],5.8,95355,DB00644,Gonadorelin
,21277965,AUC,The AUC were 5.8±0.8 and 14.5±0.4 μg h/ml and BA were 33.8±4.3% and 31.7±0.8%.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),[h·μg] / [ml],14.5,95356,DB00644,Gonadorelin
,21277965,BA,The AUC were 5.8±0.8 and 14.5±0.4 μg h/ml and BA were 33.8±4.3% and 31.7±0.8%.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),%,33.8,95357,DB00644,Gonadorelin
,21277965,BA,The AUC were 5.8±0.8 and 14.5±0.4 μg h/ml and BA were 33.8±4.3% and 31.7±0.8%.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),%,31.7,95358,DB00644,Gonadorelin
,21277965,Relative BA,Relative BA of LA from dissolving microneedles against s.c. solution was 105.6±13.5%.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),%,105.6,95359,DB00644,Gonadorelin
,21277965,half-life,The degradation rate of LA in the rat skin tissue homogenate was very fast where the half-life was 16.3±5.7 min.,Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21277965/),min,16.3,95360,DB00644,Gonadorelin
,25583642,circulation half-life,"Compared to the soluble peptide, the leuprolide-entrapped CCL-PMs showed a prolonged circulation half-life (14.4h) following a single intravenous injection in healthy rats and the released leuprolide was detected in blood for 3days.",A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25583642/),h,14.4,97545,DB00644,Gonadorelin
,10668185,maximal concentration,Dalarelin maximal concentration was 261.5 pg/cm3 and was 93.43% higher than the maximal concentration of GnRH.,Bioavailability of dalarelin--a superactive GnRH analogue--in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668185/),[pg] / [cm3],261.5,99066,DB00644,Gonadorelin
,10668185,bioavailability,"Dalarelin bioavailability was 1651.89 pg/cm3, whereas GnRH bioavailability was 718 pg/cm3 h.",Bioavailability of dalarelin--a superactive GnRH analogue--in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668185/),[pg] / [cm3],1651.89,99067,DB00644,Gonadorelin
,10668185,bioavailability,"Dalarelin bioavailability was 1651.89 pg/cm3, whereas GnRH bioavailability was 718 pg/cm3 h.",Bioavailability of dalarelin--a superactive GnRH analogue--in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668185/),[pg] / [cm3·h],718,99068,DB00644,Gonadorelin
,10668185,bioavailability level,"The bioavailability level of dalarelin was 230% compared with that for GnRH, which was accepted as a pattern of bioavailability.",Bioavailability of dalarelin--a superactive GnRH analogue--in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10668185/),%,230,99069,DB00644,Gonadorelin
,25460544,Bioavailability,Bioavailability of leuprolide following pulmonary administration was 75% higher compared to subcutaneously administered leuprolide.,Effect of protease inhibitors on pulmonary bioavailability of therapeutic proteins and peptides in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25460544/),%,75,100120,DB00644,Gonadorelin
,8748920,peak concentration,"The baseline FSH level was 2.8 IU/L, and peak concentration (6.8 IU/L) was reached 12 hours after hMG injection (median values).",Serum levels of follicle-stimulating hormone and luteinizing hormone after subcutaneous administration of human menopausal gonadotropin during pituitary suppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748920/),[iu] / [l],6.8,100767,DB00644,Gonadorelin
,20828803,half-life,The half-life of AESZ-108 was estimated to be about 2h.,"Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828803/),h,2,100942,DB00644,Gonadorelin
,20828803,maximum tolerated dose,The maximum tolerated dose of AESZ-108 in the absence of supportive medication is 267 mg/m² and this dose is recommended as starting dose for therapeutic Phase II studies.,"Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828803/),[mg] / [m²],267,100943,DB00644,Gonadorelin
,3093518,peak immunoreactive buserelin levels,"In unextracted serum samples taken at intervals after sc therapy in 11 girls, the peak immunoreactive buserelin levels of 52.2 +/- 14.8 ng/ml (mean +/- SEM) occurred at 30 min.",Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093518/),[ng] / [ml],52.2,101847,DB00644,Gonadorelin
,3093518,half-time of elimination,The half-time of elimination was 74.9 +/- 36.9 min.,Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093518/),min,74.9,101848,DB00644,Gonadorelin
,3093518,peak serum concentration,"By contrast, after the administration of 200 micrograms buserelin by metered nasal spray, the mean peak serum concentration in 10 girls was 100-fold less (0.65 +/- 0.14 ng/ml), although the halftime of elimination was almost identical.",Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093518/),[ng] / [ml],0.65,101849,DB00644,Gonadorelin
,3093518,maximal nasal absorption,Calculated relative bioavailability data indicated maximal nasal absorption of 6%.,Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093518/),%,6,101850,DB00644,Gonadorelin
less,6414544,initial,"The disappearance patterns of endogenously secreted follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from plasma of intact animals following chronic (1-4 days) infusion with gonadotropin releasing hormone (GnRH) showed multiple components, but the initial few half-lives were relatively short (less than 1 h) and about 90% of both gonadotropins were cleared from the plasma within 6 h.","Effects of gonadectomy on polymorphism in stored and circulating gonadotropins in the bullfrog, Rana catesbeiana. I. Clearance profiles. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414544/),h,1,108266,DB00644,Gonadorelin
,6414544,first half-lives,"By comparison, the disappearance rates of FSH and LH from plasma of six long-term gonadectomized males following hypophysectomy were extremely slow: first half-lives for FSH and LH were 25.6 h and 17.2 h, respectively, and subsequent half-lives were even longer.","Effects of gonadectomy on polymorphism in stored and circulating gonadotropins in the bullfrog, Rana catesbeiana. I. Clearance profiles. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414544/),h,25.6,108267,DB00644,Gonadorelin
,6414544,first half-lives,"By comparison, the disappearance rates of FSH and LH from plasma of six long-term gonadectomized males following hypophysectomy were extremely slow: first half-lives for FSH and LH were 25.6 h and 17.2 h, respectively, and subsequent half-lives were even longer.","Effects of gonadectomy on polymorphism in stored and circulating gonadotropins in the bullfrog, Rana catesbeiana. I. Clearance profiles. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414544/),h,17.2,108268,DB00644,Gonadorelin
,8842981,minimum detectable level,"The RIA is suitable for the direct determination of Antarelix in plasma, with a minimum detectable level of 1.12 fmol/assay.","Radioimmunoassay of Antarelix, a luteinizing hormone releasing-hormone antagonist, in plasma and its application for pharmacokinetic study in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842981/),[fmol] / [assay],1.12,109578,DB00644,Gonadorelin
,8842981,recovery,The recovery was 104.8% with intra- and interassay CV between 1 and 3.7%.,"Radioimmunoassay of Antarelix, a luteinizing hormone releasing-hormone antagonist, in plasma and its application for pharmacokinetic study in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842981/),%,104.8,109579,DB00644,Gonadorelin
,1531580,time to maximum concentration (Tmax),"After intravenous administration, time to maximum concentration (Tmax) was 2 minutes, and maximum serum concentration (Cmax) was 8.2 +/- 2.09 (SD) ng/ml.",Bioavailability of nafarelin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531580/),min,2,114889,DB00644,Gonadorelin
,1531580,maximum serum concentration (Cmax),"After intravenous administration, time to maximum concentration (Tmax) was 2 minutes, and maximum serum concentration (Cmax) was 8.2 +/- 2.09 (SD) ng/ml.",Bioavailability of nafarelin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531580/),[ng] / [ml],8.2,114890,DB00644,Gonadorelin
,1531580,Tmax,"For intranasal nafarelin, mean Tmax was 18.4 +/- 7.9 minutes (range, 5 to 40 minutes), and Cmax was 2.04 +/- 1.29 ng/ml (range, 0.49 to 5.7 ng/ml).",Bioavailability of nafarelin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531580/),min,18.4,114891,DB00644,Gonadorelin
,1531580,Cmax,"For intranasal nafarelin, mean Tmax was 18.4 +/- 7.9 minutes (range, 5 to 40 minutes), and Cmax was 2.04 +/- 1.29 ng/ml (range, 0.49 to 5.7 ng/ml).",Bioavailability of nafarelin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531580/),[ng] / [ml],2.04,114892,DB00644,Gonadorelin
,1531580,Systemic bioavailability,Systemic bioavailability of nafarelin ranged from 1.15% to 5.62% and averaged 2.82% +/- 1.23%.,Bioavailability of nafarelin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531580/),%,1.15,114893,DB00644,Gonadorelin
,1531580,Systemic bioavailability,Systemic bioavailability of nafarelin ranged from 1.15% to 5.62% and averaged 2.82% +/- 1.23%.,Bioavailability of nafarelin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531580/),%,5.62,114894,DB00644,Gonadorelin
,1531580,Systemic bioavailability,Systemic bioavailability of nafarelin ranged from 1.15% to 5.62% and averaged 2.82% +/- 1.23%.,Bioavailability of nafarelin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531580/),%,2.82,114895,DB00644,Gonadorelin
,10709155,absolute bioavailability,Average absolute bioavailability after SC administration was 85%.,Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709155/),%,85,115437,DB00644,Gonadorelin
,6425491,biological half-lives,"Although leuprolide disappeared rapidly from the serum after intravenous administration (the biological half-lives were 8.4 min in the alpha-phase and 33.2 min in the beta-phase), long-lasting serum levels were observed when the analogue was administered vaginally.",Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425491/),min,8.4,118883,DB00644,Gonadorelin
,6425491,biological half-lives,"Although leuprolide disappeared rapidly from the serum after intravenous administration (the biological half-lives were 8.4 min in the alpha-phase and 33.2 min in the beta-phase), long-lasting serum levels were observed when the analogue was administered vaginally.",Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425491/),min,33.2,118884,DB00644,Gonadorelin
,6425491,absolute bioavailability,"The absolute bioavailability, estimated by the AUC of serum leuprolide levels, was 25.8% over 6 h and 38.0% over 12 h in the 5% citric acid solution (pH 3.5).",Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425491/),%,25.8,118885,DB00644,Gonadorelin
,6425491,absolute bioavailability,"The absolute bioavailability, estimated by the AUC of serum leuprolide levels, was 25.8% over 6 h and 38.0% over 12 h in the 5% citric acid solution (pH 3.5).",Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425491/),%,38.0,118886,DB00644,Gonadorelin
,26325323,Maximum serum concentration (Cmax,Maximum serum concentration (Cmax = 0.11 μg/ml) was reached at 2h (Tmax) following oral administration of the compound at 10mg/kg.,In vivo pharmacological evaluation of a lactose-conjugated luteinizing hormone releasing hormone analogue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26325323/),[μg] / [ml],0.11,123092,DB00644,Gonadorelin
,26325323,Tmax,Maximum serum concentration (Cmax = 0.11 μg/ml) was reached at 2h (Tmax) following oral administration of the compound at 10mg/kg.,In vivo pharmacological evaluation of a lactose-conjugated luteinizing hormone releasing hormone analogue. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26325323/),h,2,123093,DB00644,Gonadorelin
,26325323,half-life,The half-life was determined to be 2.6h.,In vivo pharmacological evaluation of a lactose-conjugated luteinizing hormone releasing hormone analogue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26325323/),h,2.6,123094,DB00644,Gonadorelin
,26325323,absolute bioavailability,"The absolute bioavailability of the orally administered compound was found to be 14%, which was a remarkable improvement compared to zero-to-low oral bioavailability of the native peptide.",In vivo pharmacological evaluation of a lactose-conjugated luteinizing hormone releasing hormone analogue. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26325323/),%,14,123095,DB00644,Gonadorelin
,9806255,terminal half-life,The median terminal half-life ranged from 5 to 10 h in the three different dose groups.,Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806255/),h,5 to 10,127081,DB00644,Gonadorelin
,9806255,terminal half-life,The median terminal half-life of Cetrorelix varied between 20 and 80 h.,Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806255/),h,20 and 80,127082,DB00644,Gonadorelin
,12638392,terminal half-life,"A two-compartment model described the PK of CET with median terminal half-life estimates of 9.2 and 54.5 hours after SD and MD, respectively.",Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638392/),h,9.2,127252,DB00644,Gonadorelin
,12638392,terminal half-life,"A two-compartment model described the PK of CET with median terminal half-life estimates of 9.2 and 54.5 hours after SD and MD, respectively.",Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638392/),h,54.5,127253,DB00644,Gonadorelin
,12638392,IC50,"The IC50 (for suppression) estimate was 0.73 ng/ml for SD, and EC50 (surge delay) was 1.42 ng/ml for MD.",Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638392/),[ng] / [ml],0.73,127254,DB00644,Gonadorelin
,12638392,EC50,"The IC50 (for suppression) estimate was 0.73 ng/ml for SD, and EC50 (surge delay) was 1.42 ng/ml for MD.",Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12638392/),[ng] / [ml],1.42,127255,DB00644,Gonadorelin
,10593372,Peak concentrations,"Peak concentrations, which occurred approximately 1 hour after dosing, increased in a dose-proportional manner and averaged 5.2 ng/mL, 11.2 ng/mL, and 22.2 ng/mL for the 0.125-mg, 0.25-mg, and 0.50-mg doses, respectively.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593372/),[ng] / [ml],5.2,127311,DB00644,Gonadorelin
,10593372,Peak concentrations,"Peak concentrations, which occurred approximately 1 hour after dosing, increased in a dose-proportional manner and averaged 5.2 ng/mL, 11.2 ng/mL, and 22.2 ng/mL for the 0.125-mg, 0.25-mg, and 0.50-mg doses, respectively.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593372/),[ng] / [ml],11.2,127312,DB00644,Gonadorelin
,10593372,Peak concentrations,"Peak concentrations, which occurred approximately 1 hour after dosing, increased in a dose-proportional manner and averaged 5.2 ng/mL, 11.2 ng/mL, and 22.2 ng/mL for the 0.125-mg, 0.25-mg, and 0.50-mg doses, respectively.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593372/),[ng] / [ml],22.2,127313,DB00644,Gonadorelin
,10593372,area under the curve,"Corresponding mean values for the area under the curve over one dosing interval (24 hours) were 33 ng x h/mL, 77.1 ng x h/mL, and 137.8 ng x h/mL, respectively.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593372/),[h·ng] / [ml],33,127314,DB00644,Gonadorelin
,10593372,area under the curve,"Corresponding mean values for the area under the curve over one dosing interval (24 hours) were 33 ng x h/mL, 77.1 ng x h/mL, and 137.8 ng x h/mL, respectively.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593372/),[h·ng] / [ml],77.1,127315,DB00644,Gonadorelin
,10593372,area under the curve,"Corresponding mean values for the area under the curve over one dosing interval (24 hours) were 33 ng x h/mL, 77.1 ng x h/mL, and 137.8 ng x h/mL, respectively.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593372/),[h·ng] / [ml],137.8,127316,DB00644,Gonadorelin
,7937548,t1/2 of elimination,"After intratracheal administration of a 80 micrograms/kg dose, the average t1/2 of elimination was 9.8 +/- 1.3 hours (n = 5) which was similar to the elimination kinetics of a 30 micrograms/kg i.v. dose (7.2 +/- 2.9 hours).",Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937548/),h,9.8,130176,DB00644,Gonadorelin
,7937548,elimination kinetics,"After intratracheal administration of a 80 micrograms/kg dose, the average t1/2 of elimination was 9.8 +/- 1.3 hours (n = 5) which was similar to the elimination kinetics of a 30 micrograms/kg i.v. dose (7.2 +/- 2.9 hours).",Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937548/),h,7.2,130177,DB00644,Gonadorelin
,7937548,Mean residence time (MRT),"Mean residence time (MRT) was prolonged to 10.3 +/- 2.0 hours vs. 2.7 +/- 0.8 hours i.v., and mean absorption time (MAT) was calculated to be 7.5 +/- 1.8 hours.",Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937548/),h,10.3,130178,DB00644,Gonadorelin
,7937548,Mean residence time (MRT),"Mean residence time (MRT) was prolonged to 10.3 +/- 2.0 hours vs. 2.7 +/- 0.8 hours i.v., and mean absorption time (MAT) was calculated to be 7.5 +/- 1.8 hours.",Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937548/),h,2.7,130179,DB00644,Gonadorelin
,7937548,mean absorption time (MAT),"Mean residence time (MRT) was prolonged to 10.3 +/- 2.0 hours vs. 2.7 +/- 0.8 hours i.v., and mean absorption time (MAT) was calculated to be 7.5 +/- 1.8 hours.",Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937548/),h,7.5,130180,DB00644,Gonadorelin
,7937548,Maximum plasma levels (cmax),Maximum plasma levels (cmax) of 9.2 ng/ml were reached after 2 hours.,Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937548/),[ng] / [ml],9.2,130181,DB00644,Gonadorelin
,7937548,bioavailability,The average bioavailability was 9.8 +/- 3.9% of the dose.,Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937548/),%,9.8,130182,DB00644,Gonadorelin
,11213442,maximum concentration of dalarelin in the blood (Cmax),"The maximum concentration of dalarelin in the blood (Cmax), which was 261.5 pg/cm3, was observed at the maximum time (tmax) 30 min, after its subcutaneous administration.",Distribution and pharmacokinetics of the gonadotrophin releasing hormone analogue (Gn-RH analogue) dalarelin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213442/),[pg] / [cm3],261.5,131272,DB00644,Gonadorelin
,28323948,half-life,"Elagolix was rapidly absorbed after oral dosing, reaching maximum concentrations at 1.0 to 1.5 hours, with a half-life of 4 to 6 hours.",Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28323948/),h,4 to 6,136180,DB00644,Gonadorelin
,9040091,minimum detectable dose,"The assay was validated in terms of accuracy (recovery range, 94.0-105.4%), in terms of precision (intra- and interassay variations of 10.0-12.4% and 8.6-11.3%, respectively), and in terms of sensitivity (minimum detectable dose of 2.7 pg/assay).",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),[pg] / [assay],2.7,136774,DB00644,Gonadorelin
,9040091,distribution,"Following iv acute administration, a biexponential decline of plasma meterelin levels was observed, with distribution and elimination half-lives of 5.9 +/- 2.5 and 106 +/- 22 min, respectively.",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),min,5.9,136775,DB00644,Gonadorelin
,9040091,elimination half-lives,"Following iv acute administration, a biexponential decline of plasma meterelin levels was observed, with distribution and elimination half-lives of 5.9 +/- 2.5 and 106 +/- 22 min, respectively.",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),min,106,136776,DB00644,Gonadorelin
,9040091,elimination half-life,"After sc acute administration, the elimination half-life was in the range of 103 to 173 min.",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),min,103 to 173,136777,DB00644,Gonadorelin
,9040091,systemic clearance (CLT),"The systemic clearance (CLT) ranged from 1.6 to 2.6 mL/min/kg, and the volume of distribution at steady state (Vdss) varied from 285 to 438 mL/kg.",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),[ml] / [kg·min],1.6 to 2.6,136778,DB00644,Gonadorelin
,9040091,volume of distribution at steady state (Vdss),"The systemic clearance (CLT) ranged from 1.6 to 2.6 mL/min/kg, and the volume of distribution at steady state (Vdss) varied from 285 to 438 mL/kg.",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),[ml] / [kg],285 to 438,136779,DB00644,Gonadorelin
,9496327,initial half-life,"After a rapid distribution phase with an initial half-life of 1 hour, both recombinant human LH and urinary human LH were eliminated with a terminal half-life of 10-12 hours.",Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496327/),h,1,137517,DB00644,Gonadorelin
,9496327,terminal half-life,"After a rapid distribution phase with an initial half-life of 1 hour, both recombinant human LH and urinary human LH were eliminated with a terminal half-life of 10-12 hours.",Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496327/),h,10-12,137518,DB00644,Gonadorelin
,9496327,Total serum clearance,"Total serum clearance was 1.7 L/h with < 4% and 30% of the dose being eliminated in the urine for recombinant human LH and urinary human LH, respectively.",Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496327/),[l] / [h],1.7,137519,DB00644,Gonadorelin
,9496327,volume of distribution at steady-state,The volume of distribution at steady-state was approximately 10 L.,Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9496327/),l,10,137520,DB00644,Gonadorelin
,2498387,elimination half-life,"The mean serum buserelin concentrations were 101 +/- 33 (+/- SD) ng/mL 20 min and 1.12 +/- 0.12 ng/mL 360 min after its iv injection in 6 women, and the mean elimination half-life between 20 and 360 min was 51 min.",Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498387/),min,20 and 360,137837,DB00644,Gonadorelin
,2498387,elimination half-life,"The mean serum buserelin concentrations were 101 +/- 33 (+/- SD) ng/mL 20 min and 1.12 +/- 0.12 ng/mL 360 min after its iv injection in 6 women, and the mean elimination half-life between 20 and 360 min was 51 min.",Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498387/),min,51,137838,DB00644,Gonadorelin
,2498387,urinary excretion,"In therapeutic studies with buserelin nasal spray in 5 women, serum concentrations of 0.9-1.4 ng/mL were found 15 min after a single dose of 300 micrograms, intranasally, and the urinary excretion was 2.52-3.68 micrograms/24 h during daily administration of 3 doses of 300 micrograms at intervals of 8 h.",Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498387/),[μg] / [24·h],2.52-3.68,137839,DB00644,Gonadorelin
,2940625,minimum detectable concentration,This assay allowed measurement of the LHRH analog in unextracted plasma with a minimum detectable concentration of 10 pg/ml.,Radioimmunoassay of [D-Trp6]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940625/),[pg] / [ml],10,140779,DB00644,Gonadorelin
superior,2940625,elimination half-life,"In both cases, the LHRH analog showed longer plasma half-life than native LHRH with an elimination half-life superior to 80 min.",Radioimmunoassay of [D-Trp6]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940625/),min,80,140780,DB00644,Gonadorelin
,6234387,bioavailability,"Absorption was rapid and very reproducible, with peak levels occurring at 15-30 min and a bioavailability of approximately 2% relative to a subcutaneous dose.","Nasal absorption of nafarelin acetate, the decapeptide [D-Nal(2)6)]LHRH, in rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6234387/),%,2,141255,DB00644,Gonadorelin
,6210706,t1/2,The t1/2 of the rapid component of D-Trp6 LRH clearance was 18.7 +/- 1.8 (SEM) min.,Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6210706/),min,18.7,141415,DB00644,Gonadorelin
,6210706,t1/2,This was significantly longer (P less than 0.001) than the t1/2 for the LRH of 7.8 +/- 1.1 min.,Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6210706/),min,7.8,141416,DB00644,Gonadorelin
,6210706,MCRs,"The MCRs for D-Trp6 LRH and LRH were 503.4 +/- 196.4 and 1766.6 +/- 404.3 ml/min, respectively (P less than 0.01).",Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6210706/),[ml] / [min],503.4,141417,DB00644,Gonadorelin
,6210706,MCRs,"The MCRs for D-Trp6 LRH and LRH were 503.4 +/- 196.4 and 1766.6 +/- 404.3 ml/min, respectively (P less than 0.01).",Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6210706/),[ml] / [min],1766.6,141418,DB00644,Gonadorelin
,1908753,half-life of buserelin release,After the last implant injection urinary buserelin/creatinine ratios remained relatively high (greater than 5 micrograms/g creatinine) during more than 8 weeks followed by an exponential decrease (half-life of buserelin release: 15 days) to undetectable buserelin levels at 16-22 weeks after the last implantation.,The relation between pharmacokinetics and endocrine effects of buserelin implants in patients with mastalgia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1908753/),d,15,141747,DB00644,Gonadorelin
,19154507,progression-free survival,"At a median potential follow-up of 27.2 months, the median progression-free survival was 3.7 months and the median overall survival was 18.0 months.",Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19154507/),month,3.7,141835,DB00644,Gonadorelin
,19154507,overall survival,"At a median potential follow-up of 27.2 months, the median progression-free survival was 3.7 months and the median overall survival was 18.0 months.",Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19154507/),month,18.0,141836,DB00644,Gonadorelin
,19154507,survival,For the whole trial of 46 patients the median survival was 18.3 months.,Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19154507/),month,18,141837,DB00644,Gonadorelin
,3108305,plasma disappearance half-time,"The mean plasma disappearance half-time was 24 min (range, 18-30 min).",Subcutaneous administration of gonadotropin-releasing hormone: absorption kinetics and gonadotropin responses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108305/),min,24,142174,DB00644,Gonadorelin
,3108305,t1/2,"After bolus iv injection, an initial rapid phase of disappearance (t1/2, 2.8 min) was followed by a slower phase (t1/2, 33 min), falling within the 95% confidence intervals for the disappearance half-time after sc administration (12-36 min).",Subcutaneous administration of gonadotropin-releasing hormone: absorption kinetics and gonadotropin responses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108305/),min,2.8,142175,DB00644,Gonadorelin
,3108305,t1/2,"After bolus iv injection, an initial rapid phase of disappearance (t1/2, 2.8 min) was followed by a slower phase (t1/2, 33 min), falling within the 95% confidence intervals for the disappearance half-time after sc administration (12-36 min).",Subcutaneous administration of gonadotropin-releasing hormone: absorption kinetics and gonadotropin responses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108305/),min,33,142176,DB00644,Gonadorelin
,3108305,disappearance half-time,"After bolus iv injection, an initial rapid phase of disappearance (t1/2, 2.8 min) was followed by a slower phase (t1/2, 33 min), falling within the 95% confidence intervals for the disappearance half-time after sc administration (12-36 min).",Subcutaneous administration of gonadotropin-releasing hormone: absorption kinetics and gonadotropin responses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108305/),min,12-36,142177,DB00644,Gonadorelin
,3108305,peak LH responses,There was no significant difference between peak LH responses to 10 micrograms iv and sc doses of GnRH [15.2 +/- 2.5 (+/- SEM) vs. 13.2 +/- 2.2 IU/L].,Subcutaneous administration of gonadotropin-releasing hormone: absorption kinetics and gonadotropin responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108305/),[iu] / [l],15.2,142178,DB00644,Gonadorelin
,3108305,peak LH responses,There was no significant difference between peak LH responses to 10 micrograms iv and sc doses of GnRH [15.2 +/- 2.5 (+/- SEM) vs. 13.2 +/- 2.2 IU/L].,Subcutaneous administration of gonadotropin-releasing hormone: absorption kinetics and gonadotropin responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108305/),[iu] / [l],13.2,142179,DB00644,Gonadorelin
,12187267,breakthrough response,A patient with a breakthrough response after testosterone suppression on day 49 (112 ng./dl.) regained suppression (27 ng./dl.) 14 days after the second injection (day 98).,A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12187267/),ng,112,142437,DB00644,Gonadorelin
,1586387,areas-under-the-serum-concentration-versus-time-curves (AUCs),"The areas-under-the-serum-concentration-versus-time-curves (AUCs) for the 3.3 and 6.6 mg implants were 691 +/- 60 ng x h/ml and 1050 +/- 102 ng x h/ml, respectively (p less than 0.01).",Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586387/),[h·ng] / [ml],691,149703,DB00644,Gonadorelin
,1586387,areas-under-the-serum-concentration-versus-time-curves (AUCs),"The areas-under-the-serum-concentration-versus-time-curves (AUCs) for the 3.3 and 6.6 mg implants were 691 +/- 60 ng x h/ml and 1050 +/- 102 ng x h/ml, respectively (p less than 0.01).",Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586387/),[h·ng] / [ml],1050,149704,DB00644,Gonadorelin
,1586387,mean residence times (MRTs),"The mean residence times (MRTs) of buserelin after administration of 3.3 mg and 6.6 mg buserelin implant were 4.7 +/- 0.4 and 4.1 +/- 0.3 weeks, respectively (p greater than 0.05).",Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586387/),weeks,4.7,149705,DB00644,Gonadorelin
,1586387,mean residence times (MRTs),"The mean residence times (MRTs) of buserelin after administration of 3.3 mg and 6.6 mg buserelin implant were 4.7 +/- 0.4 and 4.1 +/- 0.3 weeks, respectively (p greater than 0.05).",Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586387/),weeks,4.1,149706,DB00644,Gonadorelin
,10872648,peak teverilix plasma concentrations,Geometric means of peak teverilix plasma concentrations were 4.5 ng/mL (0.5 mg teverelix) to 49.0 ng/mL (5 mg teverelix) and tmax occurred between 1 and 4 hours after dosing.,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),[ng] / [ml],4.5,150159,DB00644,Gonadorelin
,10872648,peak teverilix plasma concentrations,Geometric means of peak teverilix plasma concentrations were 4.5 ng/mL (0.5 mg teverelix) to 49.0 ng/mL (5 mg teverelix) and tmax occurred between 1 and 4 hours after dosing.,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),[ng] / [ml],49.0,150160,DB00644,Gonadorelin
,10872648,tmax,Geometric means of peak teverilix plasma concentrations were 4.5 ng/mL (0.5 mg teverelix) to 49.0 ng/mL (5 mg teverelix) and tmax occurred between 1 and 4 hours after dosing.,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),h,1 and 4,150161,DB00644,Gonadorelin
,10872648,area under the teverelix plasma concentration-time course from zero to time of the last quantifiable plasma concentration [AUC(O-tlast)],Geometric means of the area under the teverelix plasma concentration-time course from zero to time of the last quantifiable plasma concentration [AUC(O-tlast)] were 54.9 ng x h/mL (0.5 mg teverelix) to 881.8 ng x h/mL (5 mg teverelix).,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),[h·ng] / [ml],54.9,150162,DB00644,Gonadorelin
,10872648,area under the teverelix plasma concentration-time course from zero to time of the last quantifiable plasma concentration [AUC(O-tlast)],Geometric means of the area under the teverelix plasma concentration-time course from zero to time of the last quantifiable plasma concentration [AUC(O-tlast)] were 54.9 ng x h/mL (0.5 mg teverelix) to 881.8 ng x h/mL (5 mg teverelix).,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),[h·ng] / [ml],881.8,150163,DB00644,Gonadorelin
,10872648,apparent terminal half-lives,Median values for apparent terminal half-lives ranged from 24 to 75 hours.,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),h,24 to 75,150164,DB00644,Gonadorelin
,8069567,Absorption,"Absorption was low, approximately 0.01% and 0.08% by oral (PO) and ID administration respectively, compared with intravenous (i.v.) controls.",Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069567/),%,0.01,150596,DB00644,Gonadorelin
,8069567,Absorption,"Absorption was low, approximately 0.01% and 0.08% by oral (PO) and ID administration respectively, compared with intravenous (i.v.) controls.",Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069567/),%,0.08,150597,DB00644,Gonadorelin
,8069567,bioavailabilities,"An aqueous formulation and a water in oil emulsion of a lipophilic salt, a decane sulfonic acid derivative of [D-Leu6-desGly10]LH-RH ethylamide gave ID bioavailabilities of approximately 0.2% and 1%, respectively.",Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069567/),%,0.2,150598,DB00644,Gonadorelin
,8069567,bioavailabilities,"An aqueous formulation and a water in oil emulsion of a lipophilic salt, a decane sulfonic acid derivative of [D-Leu6-desGly10]LH-RH ethylamide gave ID bioavailabilities of approximately 0.2% and 1%, respectively.",Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069567/),%,1,150599,DB00644,Gonadorelin
,8069567,Absolute bioavailability,Absolute bioavailability of the drug in typical emulsion systems ranged from approximately 3 to 10% and represent an improvement of about 100 fold in gastrointestinal bioavailability of this peptide.,Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8069567/),%,3 to 10,150600,DB00644,Gonadorelin
,31429205,steady-state Tmax,"In 12 evaluable patients (part A), TAK-385 was rapidly absorbed after a single loading dose; on day 28 (maintenance dose), median steady-state Tmax was ~1-2 hours and mean t1/2z was 67-79 hours.",Phase I trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31429205/),h,1-2,151779,DB00644,Gonadorelin
,31429205,t1/2z,"In 12 evaluable patients (part A), TAK-385 was rapidly absorbed after a single loading dose; on day 28 (maintenance dose), median steady-state Tmax was ~1-2 hours and mean t1/2z was 67-79 hours.",Phase I trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31429205/),h,67-79,151780,DB00644,Gonadorelin
,12709720,time to reach peak concentration,"After a continuous subcutaneous infusion of 50 microg x kg(-1) x d(-1), abarelix concentrations peaked with the median observed time to reach peak concentration at approximately 28 days.","Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709720/),d,28,152804,DB00644,Gonadorelin
,12709720,observed maximum plasma drug concentration,"The mean observed maximum plasma drug concentration and average plasma concentration were 56.1 and 48.6 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709720/),[ng] / [ml],56.1,152805,DB00644,Gonadorelin
,12709720,average plasma concentration,"The mean observed maximum plasma drug concentration and average plasma concentration were 56.1 and 48.6 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709720/),[ng] / [ml],48.6,152806,DB00644,Gonadorelin
,12709720,observed half-life,The mean observed half-life of abarelix was 10.0 days.,"Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709720/),d,10.0,152807,DB00644,Gonadorelin
,12709720,50% inhibitory concentration,"The population pharmacodynamic estimates (percent coefficient of variation) of the 50% inhibitory concentration, maximum organ extraction ratio, and slope and sigmoidicity of the effect-concentration curve of abarelix to testosterone were 3.47 ng/mL (12.4%), 94.9 (1.3%), and 2.92 (16.2%), respectively.","Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709720/),[ng] / [ml],3.47,152808,DB00644,Gonadorelin
,15102870,IC(50)s,"The mean IC(50)s of abarelix for T, DHT, FSH, and LH were 2.08, 3.42, 6.43, 4.25 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),[ng] / [ml],2.08,153078,DB00644,Gonadorelin
,15102870,IC(50)s,"The mean IC(50)s of abarelix for T, DHT, FSH, and LH were 2.08, 3.42, 6.43, 4.25 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),[ng] / [ml],3.42,153079,DB00644,Gonadorelin
,15102870,IC(50)s,"The mean IC(50)s of abarelix for T, DHT, FSH, and LH were 2.08, 3.42, 6.43, 4.25 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),[ng] / [ml],6.43,153080,DB00644,Gonadorelin
,15102870,IC(50)s,"The mean IC(50)s of abarelix for T, DHT, FSH, and LH were 2.08, 3.42, 6.43, 4.25 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),[ng] / [ml],4.25,153081,DB00644,Gonadorelin
,15102870,relative bioavailability,The mean relative bioavailability of the depot formulation in reference to the injectable solution was 0.52.,"Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),,0.52,153082,DB00644,Gonadorelin
,15102870,t(max),"The mean t(max) and terminal t(1/2) for abarelix after administration of abarelix injectable solution and abarelix depot injection were 1 hour and 3 days and 0.22 days (5.3 h) and 13.2 days, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),h,1,153083,DB00644,Gonadorelin
,15102870,t(max),"The mean t(max) and terminal t(1/2) for abarelix after administration of abarelix injectable solution and abarelix depot injection were 1 hour and 3 days and 0.22 days (5.3 h) and 13.2 days, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),d,0.22,153084,DB00644,Gonadorelin
,15102870,terminal t(1/2),"The mean t(max) and terminal t(1/2) for abarelix after administration of abarelix injectable solution and abarelix depot injection were 1 hour and 3 days and 0.22 days (5.3 h) and 13.2 days, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),h,5.3,153085,DB00644,Gonadorelin
,15102870,terminal t(1/2),"The mean t(max) and terminal t(1/2) for abarelix after administration of abarelix injectable solution and abarelix depot injection were 1 hour and 3 days and 0.22 days (5.3 h) and 13.2 days, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),d,13.2,153086,DB00644,Gonadorelin
,10053199,absolute bioavailability,The estimate of absolute bioavailability of leuprolide was 46.7% in dogs compared with 2.7% in monkeys at an equivalent dose of 0.45 mg/kg.,Sublingual absorption of leuprolide: comparison between human and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053199/),%,46.7,153915,DB00644,Gonadorelin
,10053199,absolute bioavailability,The estimate of absolute bioavailability of leuprolide was 46.7% in dogs compared with 2.7% in monkeys at an equivalent dose of 0.45 mg/kg.,Sublingual absorption of leuprolide: comparison between human and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053199/),%,2.7,153916,DB00644,Gonadorelin
,10053199,Absolute bioavailabilities,"Absolute bioavailabilities in humans were 2.0, 2.3 and 2.4% at doses of 1.125, 2.25 and 4.5 mg, respectively.",Sublingual absorption of leuprolide: comparison between human and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053199/),%,2.0,153917,DB00644,Gonadorelin
,10053199,Absolute bioavailabilities,"Absolute bioavailabilities in humans were 2.0, 2.3 and 2.4% at doses of 1.125, 2.25 and 4.5 mg, respectively.",Sublingual absorption of leuprolide: comparison between human and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053199/),%,2.3,153918,DB00644,Gonadorelin
,10053199,Absolute bioavailabilities,"Absolute bioavailabilities in humans were 2.0, 2.3 and 2.4% at doses of 1.125, 2.25 and 4.5 mg, respectively.",Sublingual absorption of leuprolide: comparison between human and animal models. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10053199/),%,2.4,153919,DB00644,Gonadorelin
less,31033025,specific activity,"At optimal conditions of time, temperature, ligand amount, and lutetium content, DOTA-triptorelin-hydrazide was labeled with 177 Lu (specific activity not less than 925 GBq/mg).",Preclinical evaluation of new GnRH-I receptor radionuclide therapy with 177 Lu-peptide tracer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31033025/),[gbq] / [mg],925,155909,DB00644,Gonadorelin
,31033025,IC50,The values of internalization efficiency and receptor affinity of new radiopeptide binding were IC50 = 0.47 ± 0.06 vs 0.13 ± 0.01 nM for triptorelin and cellular uptake: 3.4 ± 0.7% at 1 hour and 6.8 ± 1.17% at 4 hours of the internal reference.,Preclinical evaluation of new GnRH-I receptor radionuclide therapy with 177 Lu-peptide tracer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31033025/),nM,0.47,155910,DB00644,Gonadorelin
,31033025,IC50,The values of internalization efficiency and receptor affinity of new radiopeptide binding were IC50 = 0.47 ± 0.06 vs 0.13 ± 0.01 nM for triptorelin and cellular uptake: 3.4 ± 0.7% at 1 hour and 6.8 ± 1.17% at 4 hours of the internal reference.,Preclinical evaluation of new GnRH-I receptor radionuclide therapy with 177 Lu-peptide tracer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31033025/),nM,0.13,155911,DB00644,Gonadorelin
,31033025,IC50,The values of internalization efficiency and receptor affinity of new radiopeptide binding were IC50 = 0.47 ± 0.06 vs 0.13 ± 0.01 nM for triptorelin and cellular uptake: 3.4 ± 0.7% at 1 hour and 6.8 ± 1.17% at 4 hours of the internal reference.,Preclinical evaluation of new GnRH-I receptor radionuclide therapy with 177 Lu-peptide tracer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31033025/),%,3,155912,DB00644,Gonadorelin
,10593371,peak concentration,"The mean (+/- SD) peak concentration and time of occurrence after SC administration were 14.8+/-3.2 ng/mL and 1.1+/-0.3 hours, respectively.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593371/),[ng] / [ml],14.8,156634,DB00644,Gonadorelin
,10593371,time of occurrence,"The mean (+/- SD) peak concentration and time of occurrence after SC administration were 14.8+/-3.2 ng/mL and 1.1+/-0.3 hours, respectively.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593371/),h,1.1,156635,DB00644,Gonadorelin
,10593371,half-lives,"The mean (+/- SD) half-lives after IV administration and SC administration were highly similar (12.7+/-3.7 hours and 12.8+/-4.3 hours, respectively).",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593371/),h,12.7,156636,DB00644,Gonadorelin
,10593371,half-lives,"The mean (+/- SD) half-lives after IV administration and SC administration were highly similar (12.7+/-3.7 hours and 12.8+/-4.3 hours, respectively).",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593371/),h,12.8,156637,DB00644,Gonadorelin
,10593371,AUC0-infinity (area under the concentration-time curve),"Mean (+/- SD) AUC0-infinity (area under the concentration-time curve) values of 105+/-11 ng/mL x hours and 96+/-12 ng/mL x hours were calculated for IV administration and SC administration, respectively, resulting in an absolute mean (+/- SD) bioavailability of 91.3%+/-6.7%.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593371/),[ng] / [h·ml],105,156638,DB00644,Gonadorelin
,10593371,AUC0-infinity (area under the concentration-time curve),"Mean (+/- SD) AUC0-infinity (area under the concentration-time curve) values of 105+/-11 ng/mL x hours and 96+/-12 ng/mL x hours were calculated for IV administration and SC administration, respectively, resulting in an absolute mean (+/- SD) bioavailability of 91.3%+/-6.7%.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593371/),[ng] / [h·ml],96,156639,DB00644,Gonadorelin
,10593371,bioavailability,"Mean (+/- SD) AUC0-infinity (area under the concentration-time curve) values of 105+/-11 ng/mL x hours and 96+/-12 ng/mL x hours were calculated for IV administration and SC administration, respectively, resulting in an absolute mean (+/- SD) bioavailability of 91.3%+/-6.7%.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593371/),%,91.3,156640,DB00644,Gonadorelin
>,10593371,absolute bioavailability,"Ganirelix is absorbed rapidly and extensively after SC administration, resulting in a high absolute bioavailability of >90%.",Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10593371/),%,90,156641,DB00644,Gonadorelin
,12501882,maximal concentration,"LA had a mean (SD) maximal concentration of 26.3 (12.6) ng/mL at 4.66 (1.44) hours and was detected for a mean of 37 days (range, 28-49 days).","A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501882/),[ng] / [ml],26.3,157399,DB00644,Gonadorelin
,2108885,peak concentration,"Serum leuprorelin concentrations increased immediately after injection, reaching a peak concentration (range 13.1-54.5 ng/ml), which was directly proportional to dose, within 3 h.",Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108885/),[ng] / [ml],13.1-54.5,159487,DB00644,Gonadorelin
,3083092,beta half-life,The mean beta half-life after the intravenous dosings was 2.9 h and after the subcutaneous dosings was 3.6 h.,Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),h,2.9,161103,DB00644,Gonadorelin
,3083092,beta half-life,The mean beta half-life after the intravenous dosings was 2.9 h and after the subcutaneous dosings was 3.6 h.,Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),h,3.6,161104,DB00644,Gonadorelin
,3083092,mean residence time,"The mean residence time following the intravenous dosings averaged 3.1 h and following the subcutaneous dosings averaged 4.3 h, indicating an average mean residence time at the subcutaneous injection site of 1.2 h.",Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),h,3.1,161105,DB00644,Gonadorelin
,3083092,mean residence time,"The mean residence time following the intravenous dosings averaged 3.1 h and following the subcutaneous dosings averaged 4.3 h, indicating an average mean residence time at the subcutaneous injection site of 1.2 h.",Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),h,4.3,161106,DB00644,Gonadorelin
,3083092,mean residence time,"The mean residence time following the intravenous dosings averaged 3.1 h and following the subcutaneous dosings averaged 4.3 h, indicating an average mean residence time at the subcutaneous injection site of 1.2 h.",Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),h,1.2,161107,DB00644,Gonadorelin
,3083092,volume of distribution at steady state,"The mean volume of distribution at steady state from the intravenous and subcutaneous doses were 26.5 and 37.1 L, respectively.",Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),l,26.5,161108,DB00644,Gonadorelin
,3083092,volume of distribution at steady state,"The mean volume of distribution at steady state from the intravenous and subcutaneous doses were 26.5 and 37.1 L, respectively.",Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083092/),l,37.1,161109,DB00644,Gonadorelin
,25633239,AUC0-192,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[h·iu] / [l],424.90,164547,DB00644,Gonadorelin
,25633239,AUC0-192,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[h·iu] / [l],432.75,164548,DB00644,Gonadorelin
,25633239,C max,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[iu] / [l],0.98,164549,DB00644,Gonadorelin
,25633239,C max,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[iu] / [l],0.95,164550,DB00644,Gonadorelin
,25633239,T max,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),h,24.0,164551,DB00644,Gonadorelin
,25633239,T max,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),h,24.0,164552,DB00644,Gonadorelin
,25633239,t 1/2,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),h,43.58,164553,DB00644,Gonadorelin
,25633239,t 1/2,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),h,42.58,164554,DB00644,Gonadorelin
,25633239,K e,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[1] / [h],0.0075,164555,DB00644,Gonadorelin
,25633239,K e,"No appreciable differences in key PK parameters were detected between the r-hFSH products as per non-compartmental PK analysis [i.e. for Bemfola(®) and Gonal-f(®) respectively AUC0-192 424.90 and 432.75 IU h/L, C max 0.98 and 0.95 IU/L, T max 24.0 h (range 6.0-24.0) and 24.0 h (range 9.0-24.0), t 1/2 43.58 h [standard deviation (SD 14.17)] and 42.58 h (SD 16.47), and K e 0.0075 1/h (SD 0.003) and 0.0077 1/h (SD 0.002)].",Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633239/),[1] / [h],0.0077,164556,DB00644,Gonadorelin
,10801222,Absolute bioavailability,Absolute bioavailability of cetrorelix was 100% in rats and 97% in dogs.,"Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),%,100,167024,DB00644,Gonadorelin
,10801222,Absolute bioavailability,Absolute bioavailability of cetrorelix was 100% in rats and 97% in dogs.,"Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),%,97,167025,DB00644,Gonadorelin
,10801222,population elimination half-lives,The population elimination half-lives after iv-dose were 3.0 h in rats and 9.3 h in dogs.,"Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),h,3.0,167026,DB00644,Gonadorelin
,10801222,population elimination half-lives,The population elimination half-lives after iv-dose were 3.0 h in rats and 9.3 h in dogs.,"Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),h,9.3,167027,DB00644,Gonadorelin
,10801222,IC50,"Population mean estimates of IC50 were 1.39 and 1.24 ng/ml in rats and dogs, respectively.","Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),[ng] / [ml],1.39,167028,DB00644,Gonadorelin
,10801222,IC50,"Population mean estimates of IC50 were 1.39 and 1.24 ng/ml in rats and dogs, respectively.","Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),[ng] / [ml],1.24,167029,DB00644,Gonadorelin
,25791895,absorption rate constant,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),1/[day],0.357,167174,DB00644,Gonadorelin
,25791895,absorption rate constant,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),1/[day],0.017,167175,DB00644,Gonadorelin
,25791895,mean transit time,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),d,9.5,167176,DB00644,Gonadorelin
,25791895,equilibrium dissociation constant,"The equilibrium dissociation constant of leuprolide and the typical leuprolide plasma concentration required to achieve a castration testosterone level of ≤0.5 ng/mL were 0.3 and 0.03 ng/mL, respectively.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),[ng] / [ml],0.3,167177,DB00644,Gonadorelin
,25791895,equilibrium dissociation constant,"The equilibrium dissociation constant of leuprolide and the typical leuprolide plasma concentration required to achieve a castration testosterone level of ≤0.5 ng/mL were 0.3 and 0.03 ng/mL, respectively.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),[ng] / [ml],0.03,167178,DB00644,Gonadorelin
,1900785,circulating half-lives,"The circulating half-lives of antide were 1.7 and 14.5 days for the first and second phases, respectively.",Inhibition of pituitary gonadotropin secretion by the gonadotropin-releasing hormone antagonist antide. Development of an in vitro bioassay for characterization of pharmacokinetics and pharmacodynamics of antide in circulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900785/),d,1.7,167658,DB00644,Gonadorelin
,1900785,circulating half-lives,"The circulating half-lives of antide were 1.7 and 14.5 days for the first and second phases, respectively.",Inhibition of pituitary gonadotropin secretion by the gonadotropin-releasing hormone antagonist antide. Development of an in vitro bioassay for characterization of pharmacokinetics and pharmacodynamics of antide in circulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1900785/),d,14.5,167659,DB00644,Gonadorelin
,14592699,maximum concentration,"Intra-muscular as opposed to s.c. administration led to a more rapid absorption of degarelix, reaching a mean maximum concentration of 64 and 31 ng/ml roughly 2.0 and 3.7 h after administration, respectively.","The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14592699/),[ng] / [ml],64,167892,DB00644,Gonadorelin
,14592699,maximum concentration,"Intra-muscular as opposed to s.c. administration led to a more rapid absorption of degarelix, reaching a mean maximum concentration of 64 and 31 ng/ml roughly 2.0 and 3.7 h after administration, respectively.","The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14592699/),[ng] / [ml],31,167893,DB00644,Gonadorelin
,14592699,slow absorption half-life,The slow absorption half-life was found to be 268 h ( approximately 11 days).,"The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14592699/),h,268,167894,DB00644,Gonadorelin
,3156598,binding,"With 10% plasma, the extent of binding was 31-37%, and 0.9-4.2% for nafarelin acetate and LHRH, respectively.","Plasma binding of LHRH and nafarelin acetate, a highly potent LHRH agonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3156598/),%,31-37,168707,DB00644,Gonadorelin
,3156598,binding,"With 10% plasma, the extent of binding was 31-37%, and 0.9-4.2% for nafarelin acetate and LHRH, respectively.","Plasma binding of LHRH and nafarelin acetate, a highly potent LHRH agonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3156598/),%,0.9-4.2,168708,DB00644,Gonadorelin
,27824264,encapsulation efficiency,"The encapsulation efficiency and loading content of the drug in the Luphere 3M Depot were 94.7% and 9.92% (w/w), respectively.","Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27824264/),%,94.7,168743,DB00644,Gonadorelin
,27824264,loading content,"The encapsulation efficiency and loading content of the drug in the Luphere 3M Depot were 94.7% and 9.92% (w/w), respectively.","Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27824264/),%,9.92,168744,DB00644,Gonadorelin
,17970068,radiochemical purity,The radiochemical purity of 131I-p607E was 97.85+/-2.12%.,Longitudinal microSPECt/CT imaging and pharmacokinetics of synthetic luteinizing hormone-releasing hormone (LHRH) vaccine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970068/),%,97,170223,DB00644,Gonadorelin
,17970068,cumulative radioactivity excreted via,The cumulative radioactivity excreted via urine was 30.02+/-3.82% up to day 28 p.i..,Longitudinal microSPECt/CT imaging and pharmacokinetics of synthetic luteinizing hormone-releasing hormone (LHRH) vaccine in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970068/),%,30.02,170224,DB00644,Gonadorelin
,17970068,elimination half-life (t1/2),"The elimination half-life (t1/2), Tmax and Cmax were 158.67 h, 24 h, and 0.026 percentage of injected dose per gram (%ID/g), respectively.",Longitudinal microSPECt/CT imaging and pharmacokinetics of synthetic luteinizing hormone-releasing hormone (LHRH) vaccine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970068/),h,158.67,170225,DB00644,Gonadorelin
,17970068,Tmax,"The elimination half-life (t1/2), Tmax and Cmax were 158.67 h, 24 h, and 0.026 percentage of injected dose per gram (%ID/g), respectively.",Longitudinal microSPECt/CT imaging and pharmacokinetics of synthetic luteinizing hormone-releasing hormone (LHRH) vaccine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970068/),h,24,170226,DB00644,Gonadorelin
,17970068,Cmax,"The elimination half-life (t1/2), Tmax and Cmax were 158.67 h, 24 h, and 0.026 percentage of injected dose per gram (%ID/g), respectively.",Longitudinal microSPECt/CT imaging and pharmacokinetics of synthetic luteinizing hormone-releasing hormone (LHRH) vaccine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970068/),[%·dose·injected] / [gram],0.026,170227,DB00644,Gonadorelin
,20655813,flow rate,"The separation was achieved on a Capcell-Pak C18 (2.0mmx150mm, 5microm, AQ type) column with a gradient elution of solvent A (0.05% acetic acid in deionized water/acetonitrile=85/15; v/v) and solvent B (acetonitrile) at a flow rate of 250microL/min.",Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of goserelin in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655813/),[μl] / [min],250,175377,DB00644,Gonadorelin
,20655813,m,Multiple-reaction monitoring (MRM) of the precursor-product ion transitions consisted of m/z 635.7-->m/z 607.5 for goserelin and m/z 424.0-->m/z 292.1 for cephapirin (internal standard).,Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of goserelin in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655813/),,635.7,175378,DB00644,Gonadorelin
,20655813,LOQ,The LOQ of the method was 0.1ng/mL.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of goserelin in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655813/),[ng] / [ml],0.1,175379,DB00644,Gonadorelin
,10594381,terminal t(1/2),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,12.94,176194,DB00644,Gonadorelin
,10594381,terminal t(1/2),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,13.03,176195,DB00644,Gonadorelin
,10594381,mean residence time (MRT),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,6. 85,176196,DB00644,Gonadorelin
,10594381,mean residence time (MRT),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,8.72,176197,DB00644,Gonadorelin
,10594381,C(max),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),[ng] / [ml],277.72,176198,DB00644,Gonadorelin
,10594381,C(max),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),[ng] / [ml],274. 23,176199,DB00644,Gonadorelin
,10594381,t,"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,1,176200,DB00644,Gonadorelin
,10594381,t,"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,2,176201,DB00644,Gonadorelin
,10594381,bioavailability,"Comparing the plasma concentration after i.t. administration with data after i.v. administration from a previous study undertaken in the same laboratory, the mean i.t. bioavailability was calculated as 75.80+/-45.42 and 58.97+/-18.25%.",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),%,75.80,176202,DB00644,Gonadorelin
,10594381,bioavailability,"Comparing the plasma concentration after i.t. administration with data after i.v. administration from a previous study undertaken in the same laboratory, the mean i.t. bioavailability was calculated as 75.80+/-45.42 and 58.97+/-18.25%.",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),%,58.97,176203,DB00644,Gonadorelin
,11180022,terminal half-life,Cetrorelix pharmacokinetics were described by a 2-compartment model with a terminal half-life of 56.9 +/- 27.1 hours.,"Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180022/),h,56.9,180037,DB00644,Gonadorelin
,11180022,inhibitory concentration of 50%,"The inhibitory concentration of 50% (for LH suppression) and median effective concentration (for surge shift) estimates were 3.6 ng/mL and 1.6 ng/mL, respectively.","Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180022/),[ng] / [ml],3.6,180038,DB00644,Gonadorelin
,11180022,effective concentration,"The inhibitory concentration of 50% (for LH suppression) and median effective concentration (for surge shift) estimates were 3.6 ng/mL and 1.6 ng/mL, respectively.","Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180022/),[ng] / [ml],1.6,180039,DB00644,Gonadorelin
,11180022,inhibitory concentration of 50%,"The suppression of follicle-stimulating hormone was described by a similar Emax model, with an inhibitory concentration of 50% of 7.25 ng/mL.","Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180022/),[ng] / [ml],7.25,180040,DB00644,Gonadorelin
,16044182,mean plasma concentration,"In animals perfused with 25 mg/ml fluorescein (Perfusion Experiment (PE) 1), the mean plasma concentration was 2.8 (SE 0.12) microg/ml in post-hepatic blood samples.",An in situ single-pass perfusion model for assessing absorption across the intestinal mucosa of the brushtail possum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044182/),[μg] / [ml],2.8,185998,DB00644,Gonadorelin
,16044182,mean,"When possums were perfused with 2.5 mg/ml fluorescein and 7 microg/ml LHRH (PE 2), mean plasma concentrations were 0.3 (SE 0.01) and 7.8 (SE 1.64) microg/ml fluorescein and 0.1 (SE 0.02) and 6.3 (SE 0.45) ng/ml LHRH, in the absence and presence of permeation enhancer, respectively.",An in situ single-pass perfusion model for assessing absorption across the intestinal mucosa of the brushtail possum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044182/),[μg] / [ml],0.3,185999,DB00644,Gonadorelin
,16044182,plasma concentrations,"When possums were perfused with 2.5 mg/ml fluorescein and 7 microg/ml LHRH (PE 2), mean plasma concentrations were 0.3 (SE 0.01) and 7.8 (SE 1.64) microg/ml fluorescein and 0.1 (SE 0.02) and 6.3 (SE 0.45) ng/ml LHRH, in the absence and presence of permeation enhancer, respectively.",An in situ single-pass perfusion model for assessing absorption across the intestinal mucosa of the brushtail possum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044182/),[μg] / [ml],0.3,186000,DB00644,Gonadorelin
,16044182,plasma concentrations,"When possums were perfused with 2.5 mg/ml fluorescein and 7 microg/ml LHRH (PE 2), mean plasma concentrations were 0.3 (SE 0.01) and 7.8 (SE 1.64) microg/ml fluorescein and 0.1 (SE 0.02) and 6.3 (SE 0.45) ng/ml LHRH, in the absence and presence of permeation enhancer, respectively.",An in situ single-pass perfusion model for assessing absorption across the intestinal mucosa of the brushtail possum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044182/),[μg] / [ml],7.8,186001,DB00644,Gonadorelin
,16044182,plasma concentrations,"When possums were perfused with 2.5 mg/ml fluorescein and 7 microg/ml LHRH (PE 2), mean plasma concentrations were 0.3 (SE 0.01) and 7.8 (SE 1.64) microg/ml fluorescein and 0.1 (SE 0.02) and 6.3 (SE 0.45) ng/ml LHRH, in the absence and presence of permeation enhancer, respectively.",An in situ single-pass perfusion model for assessing absorption across the intestinal mucosa of the brushtail possum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044182/),[ng] / [ml],0.1,186002,DB00644,Gonadorelin
,16044182,plasma concentrations,"When possums were perfused with 2.5 mg/ml fluorescein and 7 microg/ml LHRH (PE 2), mean plasma concentrations were 0.3 (SE 0.01) and 7.8 (SE 1.64) microg/ml fluorescein and 0.1 (SE 0.02) and 6.3 (SE 0.45) ng/ml LHRH, in the absence and presence of permeation enhancer, respectively.",An in situ single-pass perfusion model for assessing absorption across the intestinal mucosa of the brushtail possum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044182/),[ng] / [ml],6.3,186003,DB00644,Gonadorelin
,16967346,plasma half-life,The plasma half-life of LH (2.6-3.3 hr) and T (2.7 hr) match well with the literature reports.,"Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16967346/),h,2.6-3.3,191101,DB00644,Gonadorelin
,16967346,plasma half-life,The plasma half-life of LH (2.6-3.3 hr) and T (2.7 hr) match well with the literature reports.,"Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16967346/),h,2.7,191102,DB00644,Gonadorelin
,1553349,bioavailable,The s.c. injection was 94% bioavailable compared with i.v.,Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),%,94,191598,DB00644,Gonadorelin
,1553349,bioavailability,"The i.n. bioavailability averaged 2.4%, with significant subject-to-subject variability.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),%,2.4,191599,DB00644,Gonadorelin
,1553349,Plasma peak concentrations (Cmax),"Plasma peak concentrations (Cmax) with 1- and 3-mg dosages ranged between 0.24-1.6 and 0.10-11.0 ng/ml, respectively.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),[ng] / [ml],0.24-1.6,191600,DB00644,Gonadorelin
,1553349,Plasma peak concentrations (Cmax),"Plasma peak concentrations (Cmax) with 1- and 3-mg dosages ranged between 0.24-1.6 and 0.10-11.0 ng/ml, respectively.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),[ng] / [ml],0.10-11.0,191601,DB00644,Gonadorelin
,1553349,Cmax,"Mean Cmax with a 1-mg dose of solution aerosol was 0.97 ng/ml, compared with 4.4 and 11.4 ng/ml for suspension aerosols given at 1- and 2-mg bolus dosages, respectively.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),[ng] / [ml],0.97,191602,DB00644,Gonadorelin
,1553349,Cmax,"Mean Cmax with a 1-mg dose of solution aerosol was 0.97 ng/ml, compared with 4.4 and 11.4 ng/ml for suspension aerosols given at 1- and 2-mg bolus dosages, respectively.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),[ng] / [ml],4.4,191603,DB00644,Gonadorelin
,1553349,Cmax,"Mean Cmax with a 1-mg dose of solution aerosol was 0.97 ng/ml, compared with 4.4 and 11.4 ng/ml for suspension aerosols given at 1- and 2-mg bolus dosages, respectively.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),[ng] / [ml],11.4,191604,DB00644,Gonadorelin
,1553349,bioavailability,"The mean bioavailability of the suspension aerosols (28% relative to s.c. administration) was fourfold greater than that of the solution aerosol (6.6%), suggesting that LHRH analogues may be delivered systemically via the lung as aerosol dispersions.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),%,28,191605,DB00644,Gonadorelin
,1553349,bioavailability,"The mean bioavailability of the suspension aerosols (28% relative to s.c. administration) was fourfold greater than that of the solution aerosol (6.6%), suggesting that LHRH analogues may be delivered systemically via the lung as aerosol dispersions.",Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553349/),%,6.6,191606,DB00644,Gonadorelin
,3072556,plasma elimination t1/2,"After a single 300-microgram/kg intravenous dose in rats, the plasma elimination t1/2 was 1.6 hr and the plasma clearance was 3.3 ml/min/kg.","Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072556/),h,1.6,193731,DB00644,Gonadorelin
,3072556,plasma clearance,"After a single 300-microgram/kg intravenous dose in rats, the plasma elimination t1/2 was 1.6 hr and the plasma clearance was 3.3 ml/min/kg.","Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072556/),[ml] / [kg·min],3.3,193732,DB00644,Gonadorelin
,3072556,t1/2,"In the monkey, the mean t1/2 and plasma clearance were 7.1 hr and 1.3 ml/min/kg, respectively, after an 80-microgram/kg intravenous dose.","Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072556/),h,7.1,193733,DB00644,Gonadorelin
,3072556,plasma clearance,"In the monkey, the mean t1/2 and plasma clearance were 7.1 hr and 1.3 ml/min/kg, respectively, after an 80-microgram/kg intravenous dose.","Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072556/),[ml] / [kg·min],1.3,193734,DB00644,Gonadorelin
,3072556,plasma t1/2,"Long plasma t1/2 values of 18.7 and 31.6 hr were observed after single 0.2- and 1.0-mg/kg subcutaneous doses in the monkey, suggesting the possibility of subcutaneous depot formation at the injection site.","Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072556/),h,18.7,193735,DB00644,Gonadorelin
,3072556,plasma t1/2,"Long plasma t1/2 values of 18.7 and 31.6 hr were observed after single 0.2- and 1.0-mg/kg subcutaneous doses in the monkey, suggesting the possibility of subcutaneous depot formation at the injection site.","Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072556/),h,31.6,193736,DB00644,Gonadorelin
,3923123,sensitivity,The sensitivity was 3 pg per tube.,"Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3923123/),[pg] / [tube],3,202392,DB00644,Gonadorelin
,3923123,Recovery,"Recovery of buserelin added to plasma was quantitative (62.5 pg/ml, 101.6%; 125 pg/ml, 76.8% and 250 pg/ml, 63.4%).","Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3923123/),[pg] / [ml],62.5,202393,DB00644,Gonadorelin
,3923123,Recovery,"Recovery of buserelin added to plasma was quantitative (62.5 pg/ml, 101.6%; 125 pg/ml, 76.8% and 250 pg/ml, 63.4%).","Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3923123/),%,101.6,202394,DB00644,Gonadorelin
,3923123,Recovery,"Recovery of buserelin added to plasma was quantitative (62.5 pg/ml, 101.6%; 125 pg/ml, 76.8% and 250 pg/ml, 63.4%).","Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3923123/),[pg] / [ml],125,202395,DB00644,Gonadorelin
,3923123,Recovery,"Recovery of buserelin added to plasma was quantitative (62.5 pg/ml, 101.6%; 125 pg/ml, 76.8% and 250 pg/ml, 63.4%).","Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3923123/),%,76.8,202396,DB00644,Gonadorelin
,3923123,Recovery,"Recovery of buserelin added to plasma was quantitative (62.5 pg/ml, 101.6%; 125 pg/ml, 76.8% and 250 pg/ml, 63.4%).","Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3923123/),[pg] / [ml],250,202397,DB00644,Gonadorelin
,3923123,Recovery,"Recovery of buserelin added to plasma was quantitative (62.5 pg/ml, 101.6%; 125 pg/ml, 76.8% and 250 pg/ml, 63.4%).","Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3923123/),%,63.4,202398,DB00644,Gonadorelin
,3923123,peak plasma level,"A dose of 5 micrograms buserelin injected subcutaneously into 5 normal male adults, reached a peak plasma level in 45 min (mean value 119.3 +/- 47.3 pg/ml) and remained detectable for at least 4 h.","Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3923123/),[pg] / [ml],119.3,202399,DB00644,Gonadorelin
,3923123,half disappearance time,The half disappearance time was 118.8 +/- 26.0 min.,"Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3923123/),min,118.8,202400,DB00644,Gonadorelin
,29662027,absorption rate constant,"The absorption rate constant, the total body clearance, and the volume of distribution were estimated at 16.67 h-1, 514.46 mL/h, and 487.40 mL.",Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29662027/),1/[h],16.67,202805,DB00644,Gonadorelin
,29662027,total body clearance,"The absorption rate constant, the total body clearance, and the volume of distribution were estimated at 16.67 h-1, 514.46 mL/h, and 487.40 mL.",Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29662027/),[ml] / [h],514.46,202806,DB00644,Gonadorelin
,29662027,volume of distribution,"The absorption rate constant, the total body clearance, and the volume of distribution were estimated at 16.67 h-1, 514.46 mL/h, and 487.40 mL.",Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29662027/),ml,487.40,202807,DB00644,Gonadorelin
,9563139,peak serum concentration (Cmax),"The 3-month depot showed a higher median peak serum concentration (Cmax) of leuprorelin at 20.8 ng/ml than the 1-month depot at 10.7 ng/ml but, conversely, this did not influence the rise in serum testosterone levels.",Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563139/),[ng] / [ml],20.8,204441,DB00644,Gonadorelin
,9563139,peak serum concentration (Cmax),"The 3-month depot showed a higher median peak serum concentration (Cmax) of leuprorelin at 20.8 ng/ml than the 1-month depot at 10.7 ng/ml but, conversely, this did not influence the rise in serum testosterone levels.",Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563139/),[ng] / [ml],10.7,204442,DB00644,Gonadorelin
,33196464,AUC,"RESULTSIn healthy women, the amplitude of luteinizing hormone (LH) rise was similar to that after KP54, but peaked later (21.4 vs. 4.7 hours; P = 0.0002), with correspondingly increased AUC of LH exposure (169.0 vs. 38.5 IU∙h/L; P = 0.0058).",Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196464/),[iu∙h] / [l],169.0,212089,DB00644,Gonadorelin
,33196464,AUC,"RESULTSIn healthy women, the amplitude of luteinizing hormone (LH) rise was similar to that after KP54, but peaked later (21.4 vs. 4.7 hours; P = 0.0002), with correspondingly increased AUC of LH exposure (169.0 vs. 38.5 IU∙h/L; P = 0.0058).",Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196464/),[iu∙h] / [l],38.5,212090,DB00644,Gonadorelin
,27180066,Extent of Biological Availability (EBA),"The Extent of Biological Availability (EBA), calculated on the base of AUC0-∞, showed that in the form of solution buserelin and dalarelin display, respectively, only 13 and 8 % of biological availability of their suspension counterparts.",Pharmacokinetics and Bioavailability of the GnRH Analogs in the Form of Solution and Zn2+-Suspension After Single Subcutaneous Injection in Female Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27180066/),%,13,215069,DB00644,Gonadorelin
,27180066,Extent of Biological Availability (EBA),"The Extent of Biological Availability (EBA), calculated on the base of AUC0-∞, showed that in the form of solution buserelin and dalarelin display, respectively, only 13 and 8 % of biological availability of their suspension counterparts.",Pharmacokinetics and Bioavailability of the GnRH Analogs in the Form of Solution and Zn2+-Suspension After Single Subcutaneous Injection in Female Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27180066/),%,8,215070,DB00644,Gonadorelin
,32946574,terminal elimination half-life,The terminal elimination half-life ranged between 9.8 and 12.5 hours independent of dose.,Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946574/),h,9.8 and 12.5,221815,DB00644,Gonadorelin
,32946574,maximal T,Maximal LH reduction was 70 ± 7% (mean ± sd) at 6 hours after 30 mg SJX-653 versus 10 ± 43% for placebo (P = 0.0006); maximal T reduction was of 68 ± 5% at 8 hours after 60 mg SJX-653 versus 18 ± 11% for placebo (P < 0.0001).,Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946574/),%,68,221816,DB00644,Gonadorelin
,32946574,maximal T,Maximal LH reduction was 70 ± 7% (mean ± sd) at 6 hours after 30 mg SJX-653 versus 10 ± 43% for placebo (P = 0.0006); maximal T reduction was of 68 ± 5% at 8 hours after 60 mg SJX-653 versus 18 ± 11% for placebo (P < 0.0001).,Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946574/),%,18,221817,DB00644,Gonadorelin
,32946574,plasma IC50,The plasma IC50 for LH reduction was 33 ng/mL.,Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946574/),[ng] / [ml],33,221818,DB00644,Gonadorelin
,32738042,growth velocity,Mean growth velocity decreased from 8.9 cm/year at week 4 to 6.0 cm/year at week 48.,Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32738042/),[cm] / [year],8.9,223763,DB00644,Gonadorelin
,32738042,growth velocity,Mean growth velocity decreased from 8.9 cm/year at week 4 to 6.0 cm/year at week 48.,Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32738042/),[cm] / [year],6.0,223764,DB00644,Gonadorelin
,16406989,time to castrate suppression,Mean time to castrate suppression was 21.2 days (median 21).,A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406989/),d,21.2,230642,DB00644,Gonadorelin
,3158549,length of the luteal phase,There also was no change in mean length of the luteal phase (13.7 +/- 2.1 days [control] versus 13.6 +/- 1.4 days).,Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158549/),d,13.7,232142,DB00644,Gonadorelin
,3158549,length of the luteal phase,There also was no change in mean length of the luteal phase (13.7 +/- 2.1 days [control] versus 13.6 +/- 1.4 days).,Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158549/),d,13.6,232143,DB00644,Gonadorelin
,16849403,terminal elimination half-life,NBI-42902 was rapidly absorbed after oral administration with a terminal elimination half-life ranging from 2.7 +/- 0.3 to 4.8 +/- 0.8 h.,Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16849403/),h,2.7,233675,DB00644,Gonadorelin
,16849403,terminal elimination half-life,NBI-42902 was rapidly absorbed after oral administration with a terminal elimination half-life ranging from 2.7 +/- 0.3 to 4.8 +/- 0.8 h.,Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16849403/),h,4.8,233676,DB00644,Gonadorelin
≥,26502357,time to achieve,Loading doses up to 360 mg on day 1 or 360 mg on day 1 followed by 240 mg on day 2 reduced the time to achieve castrate testosterone levels from ≥ 7 to <3 days.,Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26502357/),d,7,235929,DB00644,Gonadorelin
<,26502357,time to achieve,Loading doses up to 360 mg on day 1 or 360 mg on day 1 followed by 240 mg on day 2 reduced the time to achieve castrate testosterone levels from ≥ 7 to <3 days.,Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26502357/),d,3,235930,DB00644,Gonadorelin
>,26502357,trough TAK-385 concentrations,TAK-385 doses ≥ 80 mg/d achieved sustained medical castration and trough TAK-385 concentrations >4 ng/mL.,Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26502357/),[ng] / [ml],4,235931,DB00644,Gonadorelin
,19048788,limit of quantification (LOQ),The limit of quantification (LOQ) was 0.5 ng x mL(-1).,[Determination of decapeptide LXT-101 in plasma by HPLC-MS/MS and its pharmacokinetics in Beagle dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048788/),[ng] / [ml],0.5,235934,DB00644,Gonadorelin
,19048788,AUC(0-t),"The main pharmacokinetic parameters of LXT-101 after muscle injection of 20 microg x kg(-1) were as follows, AUC(0-t): (176.8 +/- 116.7) microg x h x L(-1), MRT(0-t): (2.52 +/- 0.53) h, T(1/2): (1.4 +/- 0.3) h; CL: (0.16 +/- 0.09) L x h(-1) x kg(-1), and Vd: (0.30 +/- 0.16) L x kg(-1), respectively.",[Determination of decapeptide LXT-101 in plasma by HPLC-MS/MS and its pharmacokinetics in Beagle dogs]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048788/),[h·μg] / [l],176.8,235935,DB00644,Gonadorelin
,19048788,MRT(0-t),"The main pharmacokinetic parameters of LXT-101 after muscle injection of 20 microg x kg(-1) were as follows, AUC(0-t): (176.8 +/- 116.7) microg x h x L(-1), MRT(0-t): (2.52 +/- 0.53) h, T(1/2): (1.4 +/- 0.3) h; CL: (0.16 +/- 0.09) L x h(-1) x kg(-1), and Vd: (0.30 +/- 0.16) L x kg(-1), respectively.",[Determination of decapeptide LXT-101 in plasma by HPLC-MS/MS and its pharmacokinetics in Beagle dogs]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048788/),h,2.52,235936,DB00644,Gonadorelin
,19048788,T(1/2),"The main pharmacokinetic parameters of LXT-101 after muscle injection of 20 microg x kg(-1) were as follows, AUC(0-t): (176.8 +/- 116.7) microg x h x L(-1), MRT(0-t): (2.52 +/- 0.53) h, T(1/2): (1.4 +/- 0.3) h; CL: (0.16 +/- 0.09) L x h(-1) x kg(-1), and Vd: (0.30 +/- 0.16) L x kg(-1), respectively.",[Determination of decapeptide LXT-101 in plasma by HPLC-MS/MS and its pharmacokinetics in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048788/),h,1.4,235937,DB00644,Gonadorelin
,19048788,CL,"The main pharmacokinetic parameters of LXT-101 after muscle injection of 20 microg x kg(-1) were as follows, AUC(0-t): (176.8 +/- 116.7) microg x h x L(-1), MRT(0-t): (2.52 +/- 0.53) h, T(1/2): (1.4 +/- 0.3) h; CL: (0.16 +/- 0.09) L x h(-1) x kg(-1), and Vd: (0.30 +/- 0.16) L x kg(-1), respectively.",[Determination of decapeptide LXT-101 in plasma by HPLC-MS/MS and its pharmacokinetics in Beagle dogs]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048788/),[l] / [h·kg],0.16,235938,DB00644,Gonadorelin
,19048788,Vd,"The main pharmacokinetic parameters of LXT-101 after muscle injection of 20 microg x kg(-1) were as follows, AUC(0-t): (176.8 +/- 116.7) microg x h x L(-1), MRT(0-t): (2.52 +/- 0.53) h, T(1/2): (1.4 +/- 0.3) h; CL: (0.16 +/- 0.09) L x h(-1) x kg(-1), and Vd: (0.30 +/- 0.16) L x kg(-1), respectively.",[Determination of decapeptide LXT-101 in plasma by HPLC-MS/MS and its pharmacokinetics in Beagle dogs]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19048788/),[l] / [kg],0.30,235939,DB00644,Gonadorelin
,3279409,minimal basal level,"The plasma concentration of Flu-OH measured at months 6, 12, and 18 of treatment shows a minimal basal level of 3.4 microM with a maximal increase at 6.8 to 8.5 microM at 2 to 4 hours.",Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3279409/),μM,3.4,236332,DB00644,Gonadorelin
,3279409,maximal increase,"The plasma concentration of Flu-OH measured at months 6, 12, and 18 of treatment shows a minimal basal level of 3.4 microM with a maximal increase at 6.8 to 8.5 microM at 2 to 4 hours.",Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3279409/),μM,6.8,236333,DB00644,Gonadorelin
,2570847,release rate,The release of the drug in rats after a single subcutaneous injection exhibited pseudo-zero-order kinetics for one month in doses ranging from 0.0135 to 1.35 mg/rat; the release rate at a dose of 1.35 mg/rat was 2.8% of dose/day; after intramuscular injection the response was similar.,"Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570847/),%,2.8,236929,DB00644,Gonadorelin
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],13.1,240897,DB00644,Gonadorelin
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],20.8,240898,DB00644,Gonadorelin
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],21,240899,DB00644,Gonadorelin
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],.,240900,DB00644,Gonadorelin
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],8,240901,DB00644,Gonadorelin
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],47.4,240902,DB00644,Gonadorelin
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],54.5,240903,DB00644,Gonadorelin
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],53,240904,DB00644,Gonadorelin
,12083977,peak plasma leuprorelin concentrations (C(max)),"Mean peak plasma leuprorelin concentrations (C(max)) of 13.1, 20.8 to 21.8, 47.4, 54.5 and 53 microg/L occur within 1 to 3 hours of depot subcutaneous administration of 3.75, 7.5, 11.25, 15 and 30 mg, respectively, compared with 32 to 35 microg/L at 36 to 60 min after a subcutaneous injection of 1mg of a non-depot formulation.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],32 to 35,240905,DB00644,Gonadorelin
,12083977,volume of distribution,"Mean volume of distribution of leuprorelin is 37L after a single subcutaneous injection of 1mg, and 36, 33 and 27L after depot administration of 3.75, 7.5 and 15mg, respectively.",Clinical pharmacokinetics of depot leuprorelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),l,37,240906,DB00644,Gonadorelin
,12083977,volume of distribution,"Mean volume of distribution of leuprorelin is 37L after a single subcutaneous injection of 1mg, and 36, 33 and 27L after depot administration of 3.75, 7.5 and 15mg, respectively.",Clinical pharmacokinetics of depot leuprorelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),l,36,240907,DB00644,Gonadorelin
,12083977,volume of distribution,"Mean volume of distribution of leuprorelin is 37L after a single subcutaneous injection of 1mg, and 36, 33 and 27L after depot administration of 3.75, 7.5 and 15mg, respectively.",Clinical pharmacokinetics of depot leuprorelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),l,33,240908,DB00644,Gonadorelin
,12083977,volume of distribution,"Mean volume of distribution of leuprorelin is 37L after a single subcutaneous injection of 1mg, and 36, 33 and 27L after depot administration of 3.75, 7.5 and 15mg, respectively.",Clinical pharmacokinetics of depot leuprorelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),l,27,240909,DB00644,Gonadorelin
,12083977,Total body clearance,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[l] / [h],9.1,240910,DB00644,Gonadorelin
,12083977,Total body clearance,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),h,3.6,240911,DB00644,Gonadorelin
,12083977,Total body clearance,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[l] / [h],8.3,240912,DB00644,Gonadorelin
,12083977,Total body clearance,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),h,2.9,240913,DB00644,Gonadorelin
,12083977,elimination half-life,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),h,3.6,240914,DB00644,Gonadorelin
,12083977,elimination half-life,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[l] / [h],8.3,240915,DB00644,Gonadorelin
,12083977,elimination half-life,Total body clearance is 9.1 L/h and elimination half-life 3.6 hours after a subcutaneous 1mg injection; corresponding values after intravenous injection are 8.3 L/h and 2.9 hours.,Clinical pharmacokinetics of depot leuprorelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),h,2.9,240916,DB00644,Gonadorelin
,12083977,C(max),"A 3-month depot PLA formulation of leuprorelin acetate 11.25mg ensures a C(max) of around 20 microg/L at 3 hours after subcutaneous injection, and continuous drug concentrations of 0.43 to 0.19 microg/L from day 7 until before the next injection.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],20,240917,DB00644,Gonadorelin
,12083977,continuous drug concentrations,"A 3-month depot PLA formulation of leuprorelin acetate 11.25mg ensures a C(max) of around 20 microg/L at 3 hours after subcutaneous injection, and continuous drug concentrations of 0.43 to 0.19 microg/L from day 7 until before the next injection.",Clinical pharmacokinetics of depot leuprorelin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083977/),[μg] / [l],0.43 to 0.19,240918,DB00644,Gonadorelin
,25038408,flow rate,"The conditions for the separation of these two compounds were achieved on a ZORBAX Eclipse Plus C18 column (Agilent, 2.1 × 50 mm, 1.8 μm, Stockport, UK) in a single chromatographic run at a flow rate of 400 μL/min.",An LC-MS/MS method for the simultaneous determination of goserelin and testosterone in rat plasma for pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25038408/),[μl] / [min],400,244629,DB00644,Gonadorelin
,9396162,half-life,The half-life for the degradation of YLV in an aqueous solution of pH 7.4 at 37 degrees C was 35.9 h.,"Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),h,35.9,249556,DB00644,Gonadorelin
,9396162,activation energies,"The activation energies of the degradation in aqueous solutions at pH 2.0, 4.8, and 7.4 were 24.6, 22.1 and 23.4 kcal/mol, respectively.","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),[kcal] / [mol],24.6,249557,DB00644,Gonadorelin
,9396162,activation energies,"The activation energies of the degradation in aqueous solutions at pH 2.0, 4.8, and 7.4 were 24.6, 22.1 and 23.4 kcal/mol, respectively.","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),[kcal] / [mol],22.1,249558,DB00644,Gonadorelin
,9396162,activation energies,"The activation energies of the degradation in aqueous solutions at pH 2.0, 4.8, and 7.4 were 24.6, 22.1 and 23.4 kcal/mol, respectively.","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),[kcal] / [mol],23.4,249559,DB00644,Gonadorelin
,9396162,half-life,"In a bovine pancreas alpha-chymotrypsin solution at 37 degrees C, the half-life of YLV was 15 min at 25.6 micrograms/ml of alpha-chymotrypsin solution.","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),min,15,249560,DB00644,Gonadorelin
,9396162,half-life,"In the rat plasma, the half-life of YLV was 42.4 min (YLV 26.7 micrograms/ml plasma), and in rat liver, lung and spleen homogenates, the degradation rate constants of YLV were 37.6, 10.3 and 23.5 times larger than that in plasma solution, respectively (all fluids containing 5 mg protein/ml).","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),min,42.4,249561,DB00644,Gonadorelin
,9396162,half-life,"In the rat plasma, the half-life of YLV was 42.4 min (YLV 26.7 micrograms/ml plasma), and in rat liver, lung and spleen homogenates, the degradation rate constants of YLV were 37.6, 10.3 and 23.5 times larger than that in plasma solution, respectively (all fluids containing 5 mg protein/ml).","Degradation of a novel tripeptide, tert-butoxycarbonyl-Tyr-Leu-Val-CH2Cl, with inhibitory effect on human leukocyte elastase in aqueous solution and in biological fluids. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9396162/),,26,249562,DB00644,Gonadorelin
,2865103,urine to feces ratio,The urine to feces ratio of nafarelin-associated 14C was 4:1 in rhesus monkeys and 1:3 in rats.,"Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865103/),,4:1,250018,DB00644,Gonadorelin
,2865103,urine to feces ratio,The urine to feces ratio of nafarelin-associated 14C was 4:1 in rhesus monkeys and 1:3 in rats.,"Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865103/),,1,250019,DB00644,Gonadorelin
,2865103,terminal plasma t1/2,"Nafarelin acetate and LHRH given iv to female rhesus monkeys in approximately equimolar doses (6.5 nmol/kg) had terminal plasma t1/2 values of 120 min and 33 min, and systemic clearance values of 2.7 ml/min/kg and 31.4 ml/min/kg, respectively.","Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865103/),min,120,250020,DB00644,Gonadorelin
,2865103,terminal plasma t1/2,"Nafarelin acetate and LHRH given iv to female rhesus monkeys in approximately equimolar doses (6.5 nmol/kg) had terminal plasma t1/2 values of 120 min and 33 min, and systemic clearance values of 2.7 ml/min/kg and 31.4 ml/min/kg, respectively.","Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865103/),min,33,250021,DB00644,Gonadorelin
,2865103,systemic clearance,"Nafarelin acetate and LHRH given iv to female rhesus monkeys in approximately equimolar doses (6.5 nmol/kg) had terminal plasma t1/2 values of 120 min and 33 min, and systemic clearance values of 2.7 ml/min/kg and 31.4 ml/min/kg, respectively.","Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865103/),[ml] / [kg·min],2.7,250022,DB00644,Gonadorelin
,2865103,systemic clearance,"Nafarelin acetate and LHRH given iv to female rhesus monkeys in approximately equimolar doses (6.5 nmol/kg) had terminal plasma t1/2 values of 120 min and 33 min, and systemic clearance values of 2.7 ml/min/kg and 31.4 ml/min/kg, respectively.","Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865103/),[ml] / [kg·min],31.4,250023,DB00644,Gonadorelin
,2865103,plasma t1/2,"In female rats, the plasma t1/2 was 33.6 min for nafarelin acetate and 6.7 min for LHRH, and the systemic clearance values for nafarelin acetate and LHRH were 12.0 ml/min/kg and 57.6 ml/min/kg, respectively, after approximately equimolar doses.","Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865103/),min,33.6,250024,DB00644,Gonadorelin
,2865103,plasma t1/2,"In female rats, the plasma t1/2 was 33.6 min for nafarelin acetate and 6.7 min for LHRH, and the systemic clearance values for nafarelin acetate and LHRH were 12.0 ml/min/kg and 57.6 ml/min/kg, respectively, after approximately equimolar doses.","Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865103/),min,6.7,250025,DB00644,Gonadorelin
,2865103,systemic clearance,"In female rats, the plasma t1/2 was 33.6 min for nafarelin acetate and 6.7 min for LHRH, and the systemic clearance values for nafarelin acetate and LHRH were 12.0 ml/min/kg and 57.6 ml/min/kg, respectively, after approximately equimolar doses.","Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865103/),[ml] / [kg·min],12.0,250026,DB00644,Gonadorelin
,2865103,systemic clearance,"In female rats, the plasma t1/2 was 33.6 min for nafarelin acetate and 6.7 min for LHRH, and the systemic clearance values for nafarelin acetate and LHRH were 12.0 ml/min/kg and 57.6 ml/min/kg, respectively, after approximately equimolar doses.","Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865103/),[ml] / [kg·min],57.6,250027,DB00644,Gonadorelin
,22691297,K(D),"The typical population values of K(D), the receptor equilibrium dissociation constant of triptorelin, and C(TRP_min) to keep 95% of the patients castrated were 0.931 and 0.0609 ng/ml, respectively.",Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691297/),[ng] / [ml],0.931,250493,DB00644,Gonadorelin
,22691297,receptor equilibrium dissociation constant,"The typical population values of K(D), the receptor equilibrium dissociation constant of triptorelin, and C(TRP_min) to keep 95% of the patients castrated were 0.931 and 0.0609 ng/ml, respectively.",Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691297/),[ng] / [ml],0.0609,250494,DB00644,Gonadorelin
,22691297,C(TRP_min),"The typical population values of K(D), the receptor equilibrium dissociation constant of triptorelin, and C(TRP_min) to keep 95% of the patients castrated were 0.931 and 0.0609 ng/ml, respectively.",Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691297/),[ng] / [ml],0.0609,250495,DB00644,Gonadorelin
,21964316,P(app),"Due to the addition of gel formulations comprising 0.5% (m/v) unmodified chitosan/0.5% (m/v) GSH and 0.5% (m/v) chitosan-TGA/0.5% (m/v) GSH, the transport of leuprolide across excised mucosa was improved up to 2.06-fold and 3.79-fold, respectively, in comparison with leuprolide applied in buffer (P(app)=2.87 ± 0.77 × 10⁻⁶ cm/s).",Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21964316/),[cm] / [s],2.87,252533,DB00644,Gonadorelin
,21964316,relative bioavailability,"With the oral gel formulation comprising 8 mg of chitosan-TGA, a relative bioavailability (versus s.c. injection) of 4.5% was achieved in contrast to the control displaying a relative bioavailability of 1.2%.",Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21964316/),%,4.5,252534,DB00644,Gonadorelin
,21964316,relative bioavailability,"With the oral gel formulation comprising 8 mg of chitosan-TGA, a relative bioavailability (versus s.c. injection) of 4.5% was achieved in contrast to the control displaying a relative bioavailability of 1.2%.",Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21964316/),%,1.2,252535,DB00644,Gonadorelin
,2180316,apparent volume of distribution,"Despite the nonlinearity, the apparent volume of distribution can be approximated by a constant value of 280 ml/kg body wt for the dynamics corresponding to the three lowest and more physiological doses.",Model of the distribution and metabolism of a GnRH superagonist in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2180316/),[ml] / [kg],280,257844,DB00644,Gonadorelin
,2180316,metabolic clearance rate,The metabolic clearance rate is 4.63 ml.min-1.kg body wt-1.,Model of the distribution and metabolism of a GnRH superagonist in dogs. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2180316/),[body·kg·ml] / [min·wt],4.63,257845,DB00644,Gonadorelin
,2180316,fractional rate,The agonist injected subcutaneously diffuses to plasma at a fractional rate of 0.0265 +/- 0.0029 min-1.,Model of the distribution and metabolism of a GnRH superagonist in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2180316/),1/[min],0.0265,257846,DB00644,Gonadorelin
,2180316,maximal rate,"Disposal occurs at a maximal rate of 0.017 and 0.0055 min-1 of the amount of agonist present in the central and peripheral compartments, respectively.",Model of the distribution and metabolism of a GnRH superagonist in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2180316/),1/[min],0.017,257847,DB00644,Gonadorelin
,2180316,maximal rate,"Disposal occurs at a maximal rate of 0.017 and 0.0055 min-1 of the amount of agonist present in the central and peripheral compartments, respectively.",Model of the distribution and metabolism of a GnRH superagonist in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2180316/),1/[min],0.0055,257848,DB00644,Gonadorelin
,2180316,fractional exchange rate between compartments,The highest fractional exchange rate between compartments reaches 0.01 min-1.,Model of the distribution and metabolism of a GnRH superagonist in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2180316/),1/[min],0.01,257849,DB00644,Gonadorelin
,2180316,steady state,min-1.kg body wt-1 leads to a steady state of 1 ng/ml plasma; 90% of that level is reached 7 h after the onset of the subcutaneous input signal.,Model of the distribution and metabolism of a GnRH superagonist in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2180316/),[ng] / [ml·plasma],1,257850,DB00644,Gonadorelin
,15715483,K(i),"3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidin-2,4-dione (R-13b, NBI 42902) displayed subnanomolar binding affinity (K(i) = 0.56 nM) and was a potent functional antagonist (IC(50) = 3.0 nM in Ca(2+) flux assay) at the human GnRH receptor.","3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715483/),nM,0.56,258239,DB00644,Gonadorelin
,15715483,IC(50),"3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidin-2,4-dione (R-13b, NBI 42902) displayed subnanomolar binding affinity (K(i) = 0.56 nM) and was a potent functional antagonist (IC(50) = 3.0 nM in Ca(2+) flux assay) at the human GnRH receptor.","3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715483/),nM,3.0,258240,DB00644,Gonadorelin
,15715483,K(i),It also bound to the monkey GnRH receptor with high affinity (K(i) = 3.9 nM).,"3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715483/),nM,3.9,258241,DB00644,Gonadorelin
,15715483,C(max),"In addition, R-13bhad good plasma exposure in cynomolgus monkeys after oral administration, with a C(max) of 737 ng/mL and an AUC of 2392 ng/mL.h at a 10 mg/kg dose.","3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715483/),[ng] / [ml],737,258242,DB00644,Gonadorelin
,15715483,AUC,"In addition, R-13bhad good plasma exposure in cynomolgus monkeys after oral administration, with a C(max) of 737 ng/mL and an AUC of 2392 ng/mL.h at a 10 mg/kg dose.","3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15715483/),[ng] / [h·ml],2392,258243,DB00644,Gonadorelin
,23524040,decomposition half-lives,"With this method, stability studies demonstrated that kisspeptin-10 degraded rapidly with decomposition half-lives of 6.8 min, 2.9 min and 1.7 min at 4 °C, 25 °C, and 37 °C, respectively.",LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 (NSC 741805) and characterization of its decomposition product and pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23524040/),min,6.8,261042,DB00644,Gonadorelin
,23524040,decomposition half-lives,"With this method, stability studies demonstrated that kisspeptin-10 degraded rapidly with decomposition half-lives of 6.8 min, 2.9 min and 1.7 min at 4 °C, 25 °C, and 37 °C, respectively.",LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 (NSC 741805) and characterization of its decomposition product and pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23524040/),min,2.9,261043,DB00644,Gonadorelin
,23524040,decomposition half-lives,"With this method, stability studies demonstrated that kisspeptin-10 degraded rapidly with decomposition half-lives of 6.8 min, 2.9 min and 1.7 min at 4 °C, 25 °C, and 37 °C, respectively.",LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 (NSC 741805) and characterization of its decomposition product and pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23524040/),min,1.7,261044,DB00644,Gonadorelin
,9701702,time to reach,"After one single injection, the mean time to reach the surgical castration testosterone range is 22 days, and this effective testosterone suppression is maintained for the 3-month therapy.",Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701702/),d,22,266397,DB00644,Gonadorelin
,9701702,plasma level,"After a first plasma surge (35.70 ng/ml) occurring 2.5 h after injection and a rise between day 17 and day 31 (maximum on day 24: 0.32 ng/ml), the mean triptorelin plasma level is stable (0.06 +/- 0.05 ng/ml) and maintained until day 91.",Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701702/),ng,0.06,266398,DB00644,Gonadorelin
,1833301,half-times,The half-life of DHAS was also calculated on two subjects; two main components of decay were detected with half-times of 0.73-1.08 and 23.1-28.8 h.,"Gonadotropin, prolactin and thyrotropin pituitary secretion after exogenous dehydroepiandrosterone-sulfate administration in normal women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1833301/),h,0.73-1.08,266828,DB00644,Gonadorelin
,1833301,half-times,The half-life of DHAS was also calculated on two subjects; two main components of decay were detected with half-times of 0.73-1.08 and 23.1-28.8 h.,"Gonadotropin, prolactin and thyrotropin pituitary secretion after exogenous dehydroepiandrosterone-sulfate administration in normal women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1833301/),h,23.1-28.8,266829,DB00644,Gonadorelin
